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The interest in bone marrow adiposity (BMA) has increased over the last decade due to
its association with, and potential role, in a range of diseases (osteoporosis, diabetes,
anorexia, cancer) as well as treatments (corticosteroid, radiation, chemotherapy,
thiazolidinediones). However, to advance the field of BMA research, standardization
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of methods is desirable to increase comparability of study outcomes and foster
collaboration. Therefore, at the 2017 annual BMA meeting, the International Bone
Marrow Adiposity Society (BMAS) founded a working group to evaluate methodologies
in BMA research. All BMAS members could volunteer to participate. The working
group members, who are all active preclinical or clinical BMA researchers, searched the
literature for articles investigating BMA and discussed the results during personal and
telephone conferences. According to the consensus opinion, both based on the review of
the literature and on expert opinion, we describe existing methodologies and discuss the
challenges and future directions for (1) histomorphometry of bone marrow adipocytes,
(2) ex vivo BMA imaging, (3) in vivo BMA imaging, (4) cell isolation, culture, differentiation
and in vitro modulation of primary bone marrow adipocytes and bone marrow stromal
cell precursors, (5) lineage tracing and in vivo BMA modulation, and (6) BMA biobanking.
We identify as accepted standards in BMA research: manual histomorphometry and
osmium tetroxide 3D contrast-enhanced µCT for ex vivo quantification, specific MRI
sequences (WFI and H-MRS) for in vivo studies, and RT-qPCR with a minimal four
gene panel or lipid-based assays for in vitro quantification of bone marrow adipogenesis.
Emerging techniques are described which may soon come to complement or substitute
these gold standards. Known confounding factors and minimal reporting standards
are presented, and their use is encouraged to facilitate comparison across studies.
In conclusion, specific BMA methodologies have been developed. However, important
challenges remain. In particular, we advocate for the harmonization of methodologies,
the precise reporting of known confounding factors, and the identification of methods to
modulate BMA independently from other tissues. Wider use of existing animal models
with impaired BMA production (e.g., Pfrt−/−, KitW/W−v) and development of specific BMA
deletion models would be highly desirable for this purpose.
Keywords: bone marrow adiposity, bone marrow adipose tissue, bone marrow fat, marrow, adipocyte, standards,
methods, Bone Marrow Adiposity Society
INTRODUCTION
Bone marrow adipocytes (BMAds) reside in the bone marrow
(BM) in close contact with bone, hematopoietic cells, marrow
stromal cells, nerves, and blood vessels. Bone marrow adipose
tissue (BMAT) thus refers to BM areas where BMAds are
the predominant cell type, and BMA refers more broadly to
BMAT across all skeletal locations and metabolic states. Over
the last decades, interest in the functional role of BMAds
has gradually increased and it is now evident that BMAds
are actively involved in bone metabolism, hematopoiesis, and
energy metabolism (1, 2). In addition, a possible role for
BMAds in many diseases has emerged (3), and research groups
all over the world are investigating the origin, function, and
interaction of BMAds. However, different methods, models,
and techniques are being used, which creates a challenge to
compare or combine the results. Therefore, the International
BMAS initiated a Methodologies Working Group to describe the
existing methodologies, to identify associated challenges, and to
establish standards in reporting as guidance for future studies in
the field.
BMAT encompasses a heterogeneous population of mature
adipocytes and preadipocytes, with distinct morphologies, lipid
content, gene expression and function. Committed preadipocytes
have a fibroblast-likemorphology when observed in vitro, and are
therefore morphologically indistinguishable from the progenitor
populations encompassed within the term bone marrow stromal
cells (BMSCs). However, preadipocytes are phenotypically very
different from mature adipocytes. Preadipocytes are defined
as cells committed through adipogenesis and characterized
by the expression of early adipogenic genes (PPARy and
CEBPa) (4, 5). Mature BMAds express late adipogenic
genes (AdipoQ, Glut4, FABP4, LPL, PLIN1, ZFP423) and
contain a single large lipid droplet, therefore resembling
white adipocytes in appearance. In particular, adiponectin
(AdipoQ) expression is already present in BM preadipocytes
and stromal precursors, then increases with differentiation
(6). Additionally, Krings et al. (7) have revealed that BMAT
from whole tibiae in C57BL/6 mice possibly have a distinctive
phenotype, expressing genes characteristic of both white and
brown adipose tissue (WAT and BAT, respectively), congruent
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with the expression pattern of purified, primary human
BMAds (7–9).
Indeed, Tavassoli et al. identified in 1976 two distinct
populations of BMAds: after treatment with hemolytic
anemia-inducing agent phenylhydrazine (10) one population
remained stable while another population disappeared, and
was described as labile BMAds. These two different “stable”
and “labile” BMAd populations could be distinguished using
performic acid Schiff (PFAS) staining (11). The presence of
two different populations of BMAds localized to different
regions of the skeleton was also more recently shown by
Scheller et al. In mice, smaller BMAds (31–33µm cell diameter)
are interspersed between hematopoietic cells in the femur,
the proximal portion of the tibia, and almost all skeletal
segments that contain hematopoietic BM, while larger BMAds
(38–39 um) are localized in the distal portion of the tibiae
and phalanx [(12); Figure 1]. When challenged with cold
exposure, BMAds interspersed in the red/hematopoietic marrow
decreased in size and number, while the adipocytes localized
in the yellow/adipocytic marrow did not change. The terms
“regulated” and “constitutive” BMAT, respectively, have thus
been proposed.
BMSCs and committed BM pre-adipocytes are more easily
isolated and have seen a larger number of in vitro assays
developed than mature BMAds, which are more difficult to
handle in culture or to process in whole bone samples. In
vivo lineage tracing models have started to pave the way, while
specific markers for BMAd maturation remain to be identified.
If successful, identification of specific biomarkers at the different
stages of BM adipogenesis in bothmouse and human will provide
tools to dissect the impact of BMA in physiology and disease.
In vivo imaging technologies are being adapted from studies
of different tissues (e.g., peripheral adipose tissue) and species
(e.g., human to mouse), while novel ex vivo imaging techniques
are being adapted and developed specifically for BMAds and
BM stromal imaging. All such techniques and their limitations
and challenges are reviewed in the six sections that constitute
this review, and guidelines for reporting of BMA-related results
to maximize comparability are proposed in the concluding
remarks (Table 1). For clarity, an abbreviation table is provided
the manuscript (Table 2).
Of note, even with such significant technological advances
over the last decade, histological analysis has been a historical
contributor in the understanding of BM composition and
architecture, and is rapidly evolving through automatization
via Digital Pathology. Histomorphometry therefore remains an
important aspect of standard methodological practices in basic
or translational research as well as clinical laboratories.
In addition, although rats and non-rodent animal models
are recommended by the food and drug administration (FDA)
or European Union as a model for osteoporosis, the field of
BMA extends beyond bone health itself to the study of energy
metabolism, hematopoiesis andmetastatic bone disease, amongst
other subfields. Mice constitute very important models for these
other aspects of BMA research, especially in their quality of
premier animal for genetic studies, and are thus recognized as
preclinical model in this context. Nonetheless, we would like to
encourage the study of BMA in larger animals and other rodents,
especially when bone health and biomechanical properties of
bone are being assessed.
HISTOMORPHOMETRY
The field of bone histomorphometry was accelerated in 1976
when Dr. Parfitt published “Terminology and symbols in
bone morphometry” which lay the foundation for the first
Guideline on Bone histomorphometry (13). We can now build
on this important consensus to establish additional guidelines
on histomorphometry of BMAT. In 1987 Parfitt et al. listed
three different meanings for bone; mineralized bonematrix, bone
matrix, and bone tissue (14). Bone tissue encompasses bone and
a soft tissue within it, the BM. The BM includes hematopoietic
cells and its precursors, physically and functionally supported
by diverse BM stromal cell populations [reviewed in (15)]. The
latter is a three-dimensional network of cells in contact with
developing blood cells in the extravascular space. The known
main cell types that constitute this network are: osteogenic cells
near bone surfaces, perivascular cells associated to sinusoids,
and adipocytes. As discussed in this first section, methods
to quantify marrow components via histomorphometry are
based on different sample preparation, embedding and staining
techniques, most requiring an intermediate step of decalcification
and some allowing for epitope conservation for immunostaining.
Paraffin-embedded samples have the advantage of access to
large retrospective collections and potential comparability across
sites, especially for the clinical setting where paraffin-embedding
is standard. Other conservation procedures allow for more
precise histomorphometric quantification, and some do not
require decalcification [methyl methacrylate (MMA), or resin
embedding, including technovit 900].
Sample Preparation
Histomorphometric analysis relies predominantly on the quality
of the sample. Therefore, careful consideration of the sample
preparation is important. To prepare a BM sample, either
calcified or decalcified bone samples can be embedded in paraffin
or plastic, depending on the desired staining procedure (16, 17).
For both procedures, the BM sample is regularly fixed in 4%
Paraformaldehyde. Afterwards, the sample can be sectioned in
conventionally 4–5 µm sections.
Decalcification
Several options of decalcifying agents are available, though
Ethylenediaminetetraacetic acid (EDTA) is advised as compared
to acid-based decalcification to enable most enzymatic and
immunohistochemical stainings (18). Different factors can
control the rate of the decalcification process: concentration of
decalcifying agent, temperature, density of the sample, agitation
and thickness of the tissue. In general, a large volume (e.g., 20x
that of the sample), a high concentration of decalcifying agent
and a high temperature (e.g., 20–37◦C) during decalcification
can speed up the reaction process. In contrast, increase of the
size, density, and thickness of the sample may require longer
decalcification time (17, 18). For an optimal immunostaining,
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FIGURE 1 | (A) Distal-proximal representative images in Hematoxylin & Eosin (H&E) stain of 4µm paraffin sections of femur, tibia and tail of 8-week-old mice. Note
that the artefactually empty region in the center of tibia and femur corresponds to the expansion of the central vein lumen due to fixation-mediated retraction. (B) Left
panels: Murine bone marrow adipocytes in the tail vertebrae of 24-week-old mice (cBMAT) of 3µm paraffin sections stained with H&E (top) and 6µm sections stained
with von Kossa/Methylene Blue (bottom). Right panels: murine bone marrow adipocytes in the proximal tibia of 24 weeks-old mice (rBMAT) of 3µm paraffin sections
stained with H&E (top) and 100µm sections stained with perilipin immunofluorescence (bottom, Perilipin in green and TO-PRO-3 nuclear counterstain) of 50-week-old
mice. All images correspond to C57BL/6 female mice housed at room temperature fed ad libitum standard diet. BM, bone marrow; BMAd, bone marrow adipocyte;
CB, cortical bone; cBMAT, constitutive bone marrow adipose tissue; H&E, hematoxylin and eosin; rBMAT, regulated bone marrow adipose tissue.
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TABLE 1 | Challenges and goals ahead for the BMA field and the BMAS WG in
methodologies.
Challenges Goals
Main
challenge
Standardize Increase comparability by:
• Homogenous definitions (c.f. BMAS
consensus in nomenclature)
• Homogenous reporting (c.f. BMAS
Reporting Guidelines below)
Increase reproducibility by:
• Establishing consensus on standardized
bone sites for analysis
(e.g., rBMAT/cBMAT transition zones:
tibia, caudal vertebrae)
• Establishing consensus on reference
groups
• Establishing recommended standardized
protocols:
◦ For in vivo modulation
◦ For in vivo extraction of primary BMAd
and BMSCs
◦ For method-specific thresholds for
BMA detection
• Minimize effects of known confounding
factors, to increase inter-study and multi-
site comparison
• Increase availability and accessibility of
imaging techniques to implement use in
routine clinical practice
Technical
aspects
Adhere to
minimal
reporting
guidelines
Implement the following “BMAS Reporting
Guidelines”:
• Specify precise BMA skeletal location in
all figure legends
• Report known confounding factors for all
experiments:
◦ Skeletal location, gender, age, strain
◦ Ambient temperature (e.g., average
housing temperature)
◦ Nutritional status (e.g., average food
intake, antibiotics)
◦ Metabolic state (e.g., fasting, time of
collection)
◦ Exercise (e.g., type of enrichment
material in cages)
• Report isolation technique with sufficient
precision to reproduce; consider
depositing protocol (e.g., protocol
sharing platforms as recommended
in the BMAS working group site at
www.bma-society.org)
• Report BMAd purity (e.g.,
hematopoietic/CD45+ cells, endothelial
contamination, and CFU-F/BMSC) and
viability/intactness
• Report detailed imaging parameters,
post-processing tools and algorithms
Innovate Development of:
• Models for specific BMAd deletion
• Specific BMA biomarkers
• Recommended reference gene-set for
adipogenic differentiation
• Move from descriptive to mechanistic
studies
(Continued)
TABLE 1 | Continued
Challenges Goals
Clinical
perspectives
Define
standards
Define the normal physiological values and
increase functional understanding:
• In humans by age, gender, skeletal
location and lipid composition
• In animal models by establishing a
consensus reference group to be
included as comparison in all animal
studies (i.e., C57BL/6J 8-week-old
female mouse as homeostatic
control group)
Disseminate Facilitate access and use of unbiased BMA
methodologies to non-experts (e.g.,
automated imaging, reference gene sets,
reference cell trajectory maps)
BMA, bone marrow adiposity; BMAd, bone marrow adipocyte; BMAS, Bone Marrow
Adiposity Society; BMSC, bone marrow stromal cell; cBMAT, constitutive bone marrow
adipose tissue; CFU-F, Colony Forming Unit-Fibroblast; rBMAT, regulated bone marrow
adipose tissue.
an uniform decalcification of the sample is important, and we
recommend decalcification at room temperature or 4◦C on
constant shaking, a large volume of EDTA to sample (at least 10:1
v/v) and several refreshments of the solution (every 3–4 days) to
prevent calcium saturation (19).
Decalcification can also be performed using acidic agents to
dissolve the calcium salts from the bone. This group of agents
includes strong and weak acids. However, strong acid agents
(nitric and hydrochloric acid) should be avoided in order to
preserve the integrity of the cells and the enzymatic activity if
subsequent immunostainings are desired (20). Among the group
of weak acids (picric, acetic, and formic acid), decalcification
performed with Morse’s solution (50% formic acid and 20%
sodium citrate) can also preserve the integrity of the sample
for immunohistochemistry while allowing for high quality
architectural evaluation with Hematoxylin and Eosin (H&E)
staining (21). Dehydration is required prior to embedding.
Ethanol dehydration in graded increases of ethanol and xylene,
can allow for long-term storage of bones in 70% ethanol prior to
embedding (22).
Embedding
To embed the samples after dehydration, several options
exist. Most common and available is paraffin embedding.
Decalcification is, however, necessary. This protocol is very
useful to perform immunostaining, but the integrity of BM
content, due to the juxtaposition of hard (decalcified bone) vs.
soft (marrow) tissue is not guaranteed. Alternatives to paraffin
are MMA or technovit 900 embedding. These do not require
decalcification and allow for better preservation of the adipocyte
morphology. However MMA and technovit 900 are less available
inmost laboratories and immunohistochemical staining becomes
a challenge due to the destruction of the antigen presentation
with the conventional MMA embedding protocols (23). With all
embedding methods the histological procedure dissolves all the
lipids in the vacuole, therefore the adipocytes are referred to as
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TABLE 2 | List of abbreviations.
Abbreviation Definition
2D/3D Two/Three Dimensional
β3-AR Beta-3 Adrenergic Receptor
6 Summation
µCT Microfocus Computed Tomography
ACTH Adrenocorticotropic Hormone
Ad.Ar Adipocyte Area
Ad.Dm Adipocyte Diameter
Ad.Pm Adipocyte Perimeter
AdipoQ Adiponectin
BADGE Bisphenol A Diglycidyl Ether
BAT Brown Adipose Tissue
BM Bone Marrow
BMA Bone Marrow Adiposity
BMAS Bone Marrow Adiposity Society
BMAd Bone Marrow Adipocyte
BMAT Bone Marrow Adipose Tissue
BMD Bone Mineral Density
BMFF Bone Marrow Fat Fraction
BMSC Bone Marrow Stromal Cell
BODIPY Boron-Dipyrromethene
BV Bone Volume
cBMAds Constitutive Bone Marrow Adipocytes
CD Cluster of Differentiation
COX Cyclooxygenase-2
CR Caloric Restriction
cAMP Cyclic Adenosine Monophosphate
CEBPα CCAAT Enhancer Binding Protein Alpha
CE-CT Contrast-Enhanced Computed Tomography
CESA Contrast-Enhancing Staining Agents
CFU-F Colony-Forming Unit-Fibroblast
DAPI 4′,6-Diamidino-2-Phenylindole
DECT Dual-Energy Computed Tomography
DIO Diet Induced Obesity
DMI Cocktail for Dexamethasone, IBMX And Insulin
EDTA Ethylenediaminetetraacetic Acid
EGFP Enhanced Green Fluorescent Protein
EM Electron Microscopy
EU European Union
FABP4 Fatty Acid Binding Protein 4
FACS Fluorescence-Activated Cell Sorting
FBS Fetal Bovine Serum
FDA Food and Drug Administration
FSH Follicle Stimulating Hormone
GDPR General Data Protection Regulation
GFP Green Fluorescent Protein
GH Growth Hormone
Glut4 Glucose Transporter Type 4
H&E Hematoxylin and Eosin
1H-MRS Proton Magnetic Resonance Spectroscopy
Hf-WD-POM Hafnium Wells-Dawson Polyoxometalate
(Continued)
TABLE 2 | Continued
Abbreviation Definition
HFD High Fat Diet
HIV Human Immunodeficiency Virus
Hm.Ar Hematopoietic Area
HSL Hormone-Sensitive Lipase
IBMX Isobutylmethylxanthin
IGF-1 Insulin Growth Factor 1
IHC Immunohistochemistry
ISCT International Society for Cellular Therapy
Lepr Leptin Receptor
LPL Lipoprotein Lipase
Ma.Ar Marrow Area
Ma.V Marrow Volume
MAGP1 Microfibril-Associated Glycoprotein-1
MMA Methyl Methacrylate
MR Methionine Restriction
MRI Magnetic Resonance Imaging
N.Ad Adipocyte Number
NCD Normal Chow Diet
ORO Oil Red O
OsO4 Osmium Tetroxide
OVX Ovariectomized
PLIN1 Perilipin 1
PCR Polymerase Chain Reaction
PDGFRα Platelet Derived Growth Factor Alpha
PDFF Proton-Density Fat Fraction
PFAS Performic Acid Schiff
Ppm Parts Per Million
PPARγ Peroxisome Proliferator-Activated Receptor
Gamma
PRESS Point-Resolved Spectroscopy
P/S Penicillin/Streptomycin
PTH Parathyroid Hormone
PTRF Polymerase I and Transcript-Release Factor
rAAV Recombinant Adeno-Associated Virus
rBMAd Regulated Bone Marrow Adipocyte
RBC Red Blood Cell Lysis
RFP Red Fluorescent Protein
RNA Ribonucleic Acid
RT-qPCR Real-Time Quantitative Polymerase Chain Reaction
SFF Signal Fat Fraction
SSC Skeletal Stem Cell
STEAM Stimulated Echo Acquisition Mode
SVF Stromal Vascular Fraction
T.Ar Tissue Area
TRAP Tartrate-Resistant Acid Phosphatase
TV Tissue Volume
TZD Thiazolidinediones
UCP1 Uncoupling Protein 1
v/v Volume/Volume
VMH Ventromedial Hypothalamus
WAT White Adipose Tissue
WFI Water–Fat MR Imaging
WT Wild Type
ZFP423 Zinc Finger Protein 423
Frontiers in Endocrinology | www.frontiersin.org 6 February 2020 | Volume 11 | Article 65
Tratwal et al. BMAS Methodologies Working Group Report
“ghosts,” which makes it impossible to investigate lipid content
and composition in combination with histology.
To resolve this issue, Erben et al. developed an alternative
protocol for plastic embedding, that avoids the complete loss
of enzymatic activity in the tissue by adding methylbenzoate
during the infiltration process and polymerization of the plastic
(24). Here, cold embedding seems to be crucial for antigen
presentation in the immunohistochemical procedure. Enzymatic
activity is also preserved by using another resin embedding
system (e.g., Technovit 9100) that contains methyl methacrylate
and catalysators that allow the polymerization at low temperature
(4◦C) (25).
Staining
Although the adipocyte lipid vacuole is empty due to the ethanol-
based dehydration necessary for histological procedures, these
mature adipocyte ghosts are easily identifiable with several
standardized staining procedures. The most frequently used
in paraffin embedded bone is the H&E stain. Standardized
staining procedures for plastic embedded bone, such as Goldner’s
trichrome, toluidine blue and Von Kossa staining can also be
used to identify mature adipocyte ghost cells (24).
The discrimination between BMAds and blood vessels in a
cross section can be difficult since the BM microenvironment
is densely populated by blood vessels of different types and
diameter and the endothelial wall is not always identifiable
(26). Immunohistochemistry for Perilipin (27), a marker of
mature adipocytes, is therefore useful for identification of BMAds
in both human and murine tissues (Figure 1). Alternatively,
immunostaining for Endomucin and/or CD31, markers for
endothelial cells can be used to discriminate between blood
vessels and adipocytes (28).
Quantification
Two types of dimensional quantification are possible: two
dimensional in terms of perimeter, diameter and area, and three
dimensional in terms of volume and surface (29). Moreover, as
described in the consensus on bone histomorphometry (30) and
extensively discussed in the accompanying BMAS nomenclature
position paper, BMA parameters should be presented in relation
to a reference region (31). By using a common referent, it
is possible to assess changes in the number or percentage of
adipocytes following an intervention or comparing physiological
and pathological states. For histological measures of BMAT, two-
dimensional measurements of BMAT are applicable and two
reference areas should be used: Marrow area (Ma.Ar) and total
tissue area (T.Ar). It is important to distinguish between these
two areas since the interpretation is notably different. When
bone mass is lost and replaced by other marrow tissue, the
Ma.Ar is increased while T.Ar remains similar. Marrow adiposity
increases only when the area of BMAds increases relative to
the marrow space. For three-dimensional ex vivo or in vivo
measurement, Marrow volume (Ma.V) and Total tissue Volume
(TV) should be used. A priori, two-dimensional measures
should be used in standard bone histomorphometry and three-
dimensional measures should be reserved for techniques which
rely on 3D measurements, as discussed in the ex vivo or in vivo
sections. Three-dimensional measurements may be used in
histomorphometry when analysis of serial sections is performed
to approximate volumes.
Additionally, measurement of the size of individual adipocytes
is important in the analysis of BMAT, since the changes
in total adipose tissue can be due to either an increase in
the number of adipocytes or an increase in the size of the
adipocytes. This distinction is important since the mechanism
behind these changes can reveal both differences in adipogenic
differentiation (affecting the number) or in lipolysis (affecting
the size). In consensus with the Nomenclature working group
of the BMAS, we suggest to use the terms Perimeter (Ad.Pm),
Diameter (Ad.Dm), and mean Adipocyte Area (Ad.Ar) to
address adipocyte size. Adipocyte areas can be reported for
individual BMAds, giving rise to the frequency distribution
of BMAd areas and corresponding measurement of mean or
median Ad.Ar. In addition, adipocyte area can be reported at the
tissue level as % of total adipocyte area relative to hematopoietic
area (6Ad.Ar/Hm.Ar), tissue area (6Ad.Ar/T.Ar) or, most
commonly, to marrow area (6Ad.Ar/Ma.Ar) also commonly
reported as “marrow adipose area” or less precisely as “marrow
adiposity.” Hematopoietic area is defined either by CD45
positivity in immunohistochemistry or, morphologically, by the
areas defined by the high density of hematopoietic cell nuclei
within the marrow space. Exhaustive recommendations on BMA
nomenclature are available in the accompanying white paper
authored by the BMASWorking Group in Nomenclature (31).
Another important histological measure for adipocytes is the
density of adipocytes. This is also used to differentiate between
adipogenesis or enlargement of the adipocyte due to lipid storage.
Adipocyte density can be measured as number of adipocytes
per marrow area (N.Ad/Ma.Ar), number of adipocytes per
hematopoietic area (N.Ad/Hm.Ar) or as number of adipocytes
per tissue area (N.Ad/T.Ar). Adipocyte density varies greatly in
the endocortical vs. trabecular regions of the bone, and thus
detailed annotation and standardization of the quantified region
is paramount, as detailed in the BMAS reporting guidelines
(Table 1).
Software
To quantify these parameters, a selection of software packages are
available. Some have been developed for extramedullary adipose
tissue and require manual adipocyte measurements, while others
are designed for assessment of BM sections and are semi-
automated, with a few entirely automated (listed in Table 3).
Automated or semi-automated detection programs use shape
(roundness, circularity) and the absence of color within the lipid
vacuole for detection of BMAds. While such software packages
are not yet routine, most laboratories have developed them in-
house in order to perform adipocyte histomorphometry. Some of
these software packages are freely available online (peerJ, fathisto,
and MarrowQuant, see Table 3).
Challenges and Limitations
Histomorphometric analysis is a very useful tool to determine
the quality of bone and assess changes in the number and size of
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TABLE 3 | Description of the most used software for bone marrow histomorphometry.
Software Species, sample Automatic
or manual
Other
methods
Reported
parameters
Proposed
parameters
Other
measures
Stains
(embedding)
References
OsteoMeasure Monkey, proximal
femur
Manual – – Ad.Ar/T.Ar – – (32)
OsteoMeasure Human, biopsy Manual Blinded
count
N.Ad, % Ad.V
/TV (AV/TV); total
Ad.Pm
6Ad.Ar/T.Ar;
N.Ad/T.Ar;
total Ad.Pm
– Goldner, 20x (33)
OsteoMeasure Mouse, femur Manual – AV/TV; Ad.Pm;
N.Ad/T.Ar.
6Ad.Ar/T.Ar;
Ad.Pm;
N.Ad/T.Ar
Bone standard
histomorphometry
Goldner’s
Trichrome/Von
Kossa
(34)
OsteoMeasure Mouse, distal
femur
Manual – N.Ad/T.Ar N.Ad/T.Ar Bone standard
histomorphometry
– (35)
OsteoMeasure Proximal tibia
metaphysis
Manual – – N.Ad/T.Ar Bone standard
histomorphometry
unstained
(paraffin)
(36)
OsteoMeasure Mouse, femur Semi-
automatic
– Marrow fat
content %
(AV/TV)
6Ad.Ar/T.Ar Bone standard
histomorphometry
H&E (37)
OsteoMeasure Mouse, tibia manual – N.Ad/T.Ar;
Ad.Dm
N.Ad/T.Ar;
Ad.Dm
Bone standard
histomorphometry
TRAP/toluidine
blue
(38)
OsteoMeasure Mouse, distal
femur
Manual – Ad.Ar/T.Ar;
N.Ad/T.Ar
Ad.Ar/T.Ar;
N.Ad/T.Ar
Bone standard
histomorphometry
TRAP/toluidine
blue
(39)
OsteoMeasure Mouse, distal
femur metaphysis
Manual Fat
extraction
and analysis
Ma. adiposity;
Ad. Density
6Ad.Ar/T.Ar;
6Ad.Ar/Ma.Ar;
N.Ad/Ma.Ar
Bone standard
histomorphometry
Methyl-
methacrylate
(40)
OsteoMeasure Human, bone
biopsy
Manual – Ad.Ar/Ma.Ar Ad.Ar/Ma.Ar Bone standard
histomorphometry
unstained,
(plastic) 10x
(41)
OsteoMeasure Mouse, tibia Manual – N.Ad/T.Ar
Ad.Ar/T.Ar
N.Ad/T.Ar;
Ad.Ar/T.Ar
Bone standard
histomorphometry
H&E (42)
OsteoMeasure Mouse, distal
femur
Manual – Ad.V/TV 6Ad.Ar/T.Ar Bone standard
histomorphometry
– (43)
Image Pro Mouse, distal
femur
Manual – N.Ad; Ad.Ar Ad.Ar/T.Ar;
N.Ad/Ma.Ar
– H&E (44)
Image Pro Plus Mouse, tibia Manual – – 6Ad.Ar/T.Ar;
Ad.Ar/Ma.Ar;
N.Ad/Ma.Ar
– H&E (45)
Image Pro Plus Mouse, tibia Manual – Ad.Ar Ad.Ar/Ma.Ar Bone standard
histomorphometry
H&E (46)
Image Pro Plus v6 Rat, femur Manual Manual
count
N.Ad; Ad.Ar;
Ad.Dm, Ad.
density
6Ad.Ar/T.Ar;
6Ad.Ar/Ma.Ar;
N.Ad/Ma.Ar;
Ad.Dm
Bone standard
histomorphometry
H&E (47)
Image Pro Plus v6 Rat, femur Manual – Ad.Dm,
N.Ad/Ma.Ar
%Ad.Ar
Ad.Dm;
6Ad.Ar/T.Ar
6Ad.Ar/Ma.Ar;
N.Ad/Ma.Ar
Bone standard
histomorphometry
H&E (48)
Image Pro Plus v6 Rabbit, distal
femur
Manual – Ad.Dm;
N.Ad/Ma.Ar;
Ad.Ar/Ma.Ar
Ad.Dm;
N.Ad/Ma.Ar;
6Ad.Ar/Ma.Ar
– H&E (49)
ImageJ Rat, proximal tibia Manual – Ad. content
(Ad.Ar, T.Ar)
Ad.Ar;
6Ad.Ar/T.Ar
– H&E (50)
ImageJ Mouse, femur or
tibia
Manual – Ad.V/Ma.V 6Ad.Ar/Ma.Ar Bone standard
histomorphometry
H&E (plastic
or paraffin)
20x
(51)
ImageJ Rat, proximal tibia Manual – N.Ad/T.Ar;
Ad.Ar/T.Ar
N.Ad/T.Ar;
Ad.Ar/T.Ar
– H&E (52)
ImageJ Mouse, distal
femoral
metaphysis
Automatic/
manual
OsteoMeasure T.Ar adiposity,
N.Ad/T.Ar,
adiposity (%)
6Ad.Ar/T.Ar;
6Ad.Ar/Ma.Ar;
N.Ad/T.Ar;
N.Ad/Ma.Ar
– Von Kossa
tetrachrome
(53)
(Continued)
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TABLE 3 | Continued
Software Species, sample Automatic
or manual
Other
methods
Reported
parameters
Proposed
parameters
Other
measures
Stains
(embedding)
References
OsteoidHisto Human, biopsy Semi-
automatic
– Ad.V/TV;
Ad.V/Ma.V
Ad.Dm
N.Ad/Ma.Ar
6Ad.Ar/T.Ar;
6Ad.Ar/Ma.Ar;
Ad.Dm;
N.Ad/Ma.Ar
Bone standard
histomorphometry
Goldner’s
Trichrome
(54)
OsteoidHisto Mouse, tibia Semi-
automatic
– Ad.V/TV
Ad.V/Ma.V
Ad.Dm Ad.Dm
6Ad.Ar/T.Ar;
6Ad.Ar/Ma.Ar;
Ad.Dm;
N.Ad/T.Ar
Bone standard
histomorphometry
Calcein
blue/TRAP
(55)
Bioquant Osteo Human, biopsy Semi-
automatic
Blinded
count
N.Ad, Ad. size, N.Ad/Ma.V;
6Ad.Ar/Ma.Ar
Bone standard
histomorphometry
– (56)
Bioquant Osteo Rat, tibia Manual – N.Ad/TV N.Ad/T.Ar Bone standard
histomorphometry
Goldner’s
trichrome
(57)
Bioquant Osteo II Mouse, femur No
information
– AV/TV 6Ad.Ar/T.Ar Bone standard
histomorphometry
Goldner’s
Trichrome or
TRAP
(58)
Leica Q-win Plus Rabbit, vertebrae No
information
– Ad.Dm;
N.Ad/Ma.Ar
Ad.Dm;
N.Ad/Ma.Ar
– Oil-Red-O (59)
MarrowQuant Mouse, skeleton Semi-
automatic
Osmium
tetroxide
stain with
µCT
T.Ar; Ma.Ar;
N.Ad; Ad.Ar;
6Ad.Ar/Ma.Ar;
Ad.V (µCT)
T.Ar; Ma.Ar;
N.Ad; Ad.Ar;
6Ad.Ar/Ma.Ar;
N.Ad/Ma.Ar
Bone Ar,
hematopoietic
Ar, vascular Ar
H&E (paraffin)
20x
(60, 61)
MarrowQuant Mouse, tibia Semi-
automatic
– T.Ar; Ma.Ar;
Ad.Ar;
6Ad.Ar/Ma.Ar
T.Ar; Ma.Ar;
N.Ad; Ad.Ar;
6Ad.Ar/Ma.Ar;
N.Ad/Ma.Ar
hematopoietic
Ar, vascular Ar
H&E (paraffin) [Rojas-Sutterlin
et al. as
reviewed in
(61, 62)]
Metamorph Mouse, femur Semi-
automatic
– Ad.Ar; N.Ad 6Ad.Ar/T.Ar;
N.Ad/Ma.Ar;
Ad.Dm
– H&E (63)
Ad., adipocyte; Ad.Ar, adipocyte area; Ad.Dm, adipocyte diameter; N.Ad, adipocyte number; Ar, Area; Ma., marrow; Ma.Ar, marrow area; AV, total adipocyte volume; H&E, hematoxylin
and eosin; TRAP, tartrate-resistant acid phosphatase; TV, total tissue volume; 6, summation; µCT, micro-computerized tomography.
cells. One of the limitations is that histomorphometry is a time-
consuming technique requiring microscopy, software and/or
manual quantification. In addition, it is a technique that until
now has relied on the interpretation of the single investigator, and
therefore demands a solid quality control system. The detection
of BMAds can be hampered by the close connection of adipocytes
in yellow/adipocytic areas, making the separation and adequate
counting of clustered adipocytes a big challenge, in particular if
membranes are not intact. In mice, the number of adipocytes in
long bones tends to be lower in sites of regulated BMAT, and thus
separate adipocytes can be more easily discerned and counted in
the red/hematopoietic marrow.
However, the distinction of adipocytes from small blood
vessels can be a challenge, whether for manual quantification or
automated algorithms, especially in the younger animals or in
the context of marrow regeneration. Additional immunostains to
discern microvasculature from adipocyte ghosts are thus highly
recommended as a validation step. Moreover, one must keep
in mind that histological sections are a cross-section of the
bone/marrow organ and thus of the BMAd itself. In general,
validation of automatic detection of adipocytes is not described,
neither by presenting data on quality control measurements
nor by comparison with a manual method. We therefore
consider manual detection of adipocytes the gold standard for
histomorphometry until automated software packages have been
validated. Annotation and standardization of the quantified
region, as well as reporting of the experimental parameters
as detailed in the BMAS reporting guidelines (Table 1)
cannot be emphasized enough. Additionally, correlation of
histomorphometry findings with ex vivo or in vivo bone
measurements of lipid content to calcified tissue constitutes
a much-valued biological validation of findings. Finally, a
recommendation on which bone may be considered as standard
for reporting is premature, but we agree that choosing areas
of transition between regulated and constitutive BMAT is most
informative (e.g., tibia and/or caudal tail for mice).
EX VIVOWHOLE-BONE IMAGING
Histological slicing and histomorphometry remain the gold
standard for the ex vivo evaluation and characterization of
biological tissues in general, and BMAT in particular, by
measuring adipocyte cell size and cell number. However,
histological assessment (sectioning, staining, imaging, and
analysis) remains a challenging, time-consuming, and often
costly technique (29). Moreover, spatial patterns as well as the
spatial inter-relationship between different tissues within one
sample (for example BMAT in relation to bone and vasculature)
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can be inaccurate or impossible. To overcome some of the
limitations of 2D analyses, several 3D imaging techniques have
emerged to quantify the morphometry, spatial distribution of
BMAT and its inter-relationship with other tissues in the
marrow. In addition, mass spectrometry and high-profile liquid
chromatography remain complementary standard methods to
dissect lipid composition upon extraction (64, 65).
Contrast-Enhanced Microfocus Computed
Tomography
X-ray microfocus computed tomography (µCT) is a very
powerful tool for 3D imaging of mineralized tissues (66). High-
resolution µCT (<2µm voxel size) and nanoCT [down to
150 nm (67)] scans are achievable and a high field of view
to voxel size ratio can be obtained (68). While one of the
biggest advantages of µCT is its non-destructive character,
a considerable limitation of this technology is its lack of
specificity for soft tissues. Phase contrast µCT is a possible
solution, as it can be used to, for example, enhance edges,
which allows a better visualization of soft tissues (69). Indeed,
it provides information concerning changes in the phase of
an X-ray beam that passes through an object. Moreover, it
uses monochromatic X-rays, resulting in accurate measures of
the attenuation coefficient, and thus enabling quantitative µCT
imaging. This technique requires, however, highly dedicated
hard- and software, and is not readily available. In addition,
to the best of our knowledge, phase contrast imaging has so
far not been used to visualize BMAT. Therefore, the focus of
this review is rather on desktop single energy, polychromatic
absorption contrast-enhanced µCT (CE-CT) imaging. Although
having its limitations in the cone-beam shape of the X-ray
bundle and the lower X-ray flux compared to synchrotron µCT,
scanning times down to 15min for high-resolution imaging can
be achieved nowadays. For this kind of CE-CT, typically, there
are two kinds of contrast agents used for the visualization of
soft tissues: perfusion contrast agents, mostly used for in vivo
or ex vivo indirect imaging of vasculature, and contrast agents
that bind to the tissues for ex vivo imaging, further referred to
as contrast-enhancing staining agents (CESAs). Here, we will
focus on CESAs, which have proven to allow CE-CT imaging
of BMAT.
The introduction of CESAs has enabled contrast-enhanced
CE-CT to become a very important tool in biomedical
imaging. CESAs bind to tissues of interest, increasing the X-ray
attenuation coefficient (70). The very first reports on the use
of CESAs for CE-CT imaging of soft tissues go back to only
about a decade ago. Indeed, several groups (71–73) used osmium
tetroxide (OsO4) on mouse embryos, pig lungs, and honeybees,
respectively, to enable virtual 3D anatomical analyses using CE-
CT. Although in these studies OsO4 was used for general tissue
staining, it is well-known for its specific binding to unsaturated
lipids (74, 75). Consequently, several years later, Scheller et al.
reported the use of OsO4 for 3D CE-CT visualization of BMAT
and quantification of its amount and distribution in long bones
of mice using standardµCT (12, 76) and subsequently, ultrahigh-
resolution µCT (77).
OsO4-based BMAT characterization requires a two-step
scanning protocol: first, bones are detached and thoroughly
cleaned from soft tissues, fixed, and scanned to enable
characterization of 3D calcified bone parameters. The fixed
bones are subsequently decalcified and then stained with OsO4
for 48 h (76) or longer if the mouse models develop severe
BMAT accumulation. Subsequently, OsO4-stained bones are
rescanned. These images provide 3D quantification of BMAT
structural properties, such as adipocyte volume/total volume
(Ad.V/TV), adipocyte volume/marrow volume (Ad.V/Ma.V),
and adipocyte volume/bone volume (Ad.V/BV), which are
quantified based on the amount of osmium-bound lipid. When
combining OsO4 staining with high-resolution µCT imaging,
individual adipocytes can be distinguished (Figures 2A,C,E)
and a distribution of diameter can be calculated. When
combined with image coordinate registration, this technique
allows alignment of both the BMAT distribution and bone
micro-architecture, as well as calculation of the distance of the
BMAds from the bone surface (80). Some studies have also
used this approach to measure BMAd density (cells/mm2 Ma.V)
(81). The use of OsO4 for CE-CT-based BMAT visualization
in mouse bones has quickly become widespread due to its
compatibility with existing µCT infrastructure, ease of use,
and reasonable cost (63, 82–84). As with most techniques, a
high level of standardization is needed for each step in the
procedure (fixation, decalcification, OsO4 staining, imaging, and
analysis). For example, insufficient decalcification can lead to
problematic osmium penetration and staining (85). Indeed, the
limited tissue penetration capability makes staining of dense
regions of adipocytes or larger bones problematic, restricting this
technique primarily to whole bones in mice. Moreover, OsO4
staining is highly toxic, needing careful handling within a fume
hood and appropriate disposal (86, 87).
To overcome these limitations, a recent study by Kerckhofs
et al. reported the simultaneous visualization of mineralized
and soft tissue structures within bones (Figure 2F) utilizing
Hafnium Wells-Dawson polyoxometalate (Hf-WD-POM) as
CESA (78). For this technique, murine long bones are incubated
in POM powder dissolved in phosphate buffered saline while
shaking gently for 48-h to 5-days. Samples are then scanned
in the staining solution, or wrapped in parafilm and put in
a sample holder for scanning. Thanks to the combination of
the hydrophobic behavior of adipocytes and the binding of Hf-
WD-POM to the BM tissue, visualization of the adipocytes
is possible. When combining this CESA with high-resolution
scanning (about 2µm voxel size, maximum total image volume
about 6× 4.8× 6 mm3), BMAds can be imaged at the single cell
level (Figures 2B,D,F). This not only facilitates measurement of
the volume fraction of BMAT within the bone (Ad.V), but also
enables the quantification of the BMAd Number (N.Ad), density
(N.Ad/TV), and Diameter (Ad.Dm). Additionally, with sufficient
contrast, the vascular network can be discriminated from the
other marrow tissues. This allows for full 3D blood vessel
network assessment (i.e., branching and spatial distribution).
Hence, Hf-WD POM-based CE-CT provides complementary
data to standard histomorphometry, with enhanced 3D spatial
information and inter-relation between different tissues in the
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FIGURE 2 | Zoom of a longitudinal CE-CT cross-section of the metaphysis of a murine tibia from a 16-week-old C57BL/6Rj male mouse fed ad libitum standard diet,
using (A) osmium tetroxide and (B) Hf-WD POM staining, on the same sample. The orange arrows indicate the same adipocyte. The black arrow in (B) indicates the
bone and the white arrow indicates a blood vessel. Zoom of a longitudinal CE-CT cross-section of the diaphysis of a murine long bone using (C) osmium tetroxide and
(D) Hf-WD POM staining on the same sample. Scale bars = 250µm. 3D rendering of (E) an osmium tetroxide stained murine femur (left) and tibia (right) from an
11-week-old C57BL/6J male fed ad libitum standard diet at room temperature, where adipocytes are presented in dark gray and bone in light gray. (F) Hf-WD POM
stained murine tibia from a 30-week-old C57BL/6Rj male mouse fed high fat diet for 22 weeks [reprinted with permission from (78)], where white represents the bone,
orange the blood vessels and yellow the marrow adipocytes. (G) 3D EM image of an adipocyte [reprinted with permission from (79)]. Lipid is shown in gray,
mitochondria in green, cytoplasm in semi-transparent yellow, vascular sinusoid in red, perivascular cells in pink and orange, and blood cells in turquoise.
BM compartment (Figure 2F). This was recently used to show
that BMAT increased after menopause, and that increased
BMAT was associated with osteoporosis and prevalent vertebral
fractures (55). It should be highlighted that Hf-WD POM is non-
invasive and non-toxic, and does not interfere with subsequent
histological processing and immunostaining. A limitation of Hf-
WD POM, however, is that it is not yet commercially available,
although it can be requested in the frame of a collaboration.
Whenmaking a direct comparison betweenHf-WDPOM and
OsO4 using high-resolution CE-CT, it was observed that both
CESAs performed equally well for detecting BMAds (Figure 2).
For locations with a low to medium BMAT amount, however,
OsO4 staining was more sensitive in visualizing the sparsely
distributed adipocytes (Figures 2A,B). For medium to high
BMAT content, OsO4 tended to overestimate the adipocyte
size due to high contrast difference between stained adipocytes
and background, and thus contributed to the partial volume
effect (Figures 2C,D). For this condition, Hf-WD POM allowed
more accurate separation of individual adipocytes. Advantages
and disadvantages of these ex vivo techniques are summarized
in Table 4.
Future Challenges: 3D Microscopy
In recent years, standard microscopy techniques have also been
optimized to gain 3D information about whole-bone cellular
networks and nanoscale insight into the microenvironment of
single cells. For example, tissue clearing strategies in skeletal
tissues allow mapping of vascular networks and cell distributions
in whole bones using light-sheet or two-photon microscopy
(88, 89). Similarly,>50µm-thick section immunohistochemistry
can provide ex vivo insight into cell localization in 3D
via conventional confocal microscopy (90). Though not yet
published, we anticipate that clearing techniques described for
marrow tissue will be used to provide novel information about
BMAT localization and function. A key advantage relative to CT-
based analyses is the ability to interrogate local cells and pathways
that are defined based on expression of specific proteins and
biomolecules using antibodies or genetically modified rodents.
At the nanoscale, focused ion beam scanning electron
microscopy (EM), a form of serial EM that allows for 3D
reconstructions at subcellular resolution, was recently applied
to the BMAT adipocyte niche (79). This work builds upon
previous 2D EM analyses of BMAT (11) and has helped to
define interactions of BMAT with surrounding cells at the
endothelial interface, within the hematopoietic milieu, and at the
bone surface (Figure 2G). The major limitation of all of these
techniques is the need for specialized imaging equipment. In
many instances, data handling and analysis paradigms, which
require very sophisticated statistical analysis to correct for the
boundaries imposed by the confined bone architecture (91), are
also just beginning to emerge. In any case, the development of
regularly revised common standards and the commitment to
BMAS reporting guidelines, as specified in Table 1, will increase
comparability and pave the way for the comparative studies
necessary to determine future gold standards in this rapidly
evolving field.
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TABLE 4 | Main quantitative parameters assessed when using ex vivo imaging techniques to explore bone marrow adipose tissue.
Parameters Method Advantages Limitations
2D techniques Histomorphometry
• Adipocyte number (N.Ad)
• Adipocyte size (Ad.V)
• Adipocyte density
(N.Ad/Ma.Ar)
• Spatial localization (2D)
Resin, paraffin, or frozen sections
(<5–10µm)
• General availability
• Can be used in all species
• Pairs well with
histological stains
• Slice/region bias
• Limited field of view
• Time consuming
• High cost
3D techniques µCT—Osmium
• BMAT volume (mm3)
• BMAT density (%)
• Adipocyte number* (N.Ad)
• Adipocyte size* (Ad.V)
• Spatial localization (3D)
• Whole bones or tissue
samples, decalcified, and
stained in osmium tetroxide
solution.
• Samples imaged and analyzed
with µ- or high-resolution CT
• Adapts existing CT
infrastructure and analysis
techniques
• Simple protocol
• Low cost
• Commercially available
reagents
• Highly sensitive for
sparse BMAds
• Poor penetration in large, or high
adiposity samples
• Two-step scanning protocol for
bone and BMAT analyses
• Overestimates Ad.Dm
• Highly toxic
µCT—POM
• BMAT volume (mm3)
• BMAT density (%)
• Adipocyte number* (N.Ad)
• Adipocyte size* (Ad.V)
• Spatial localization (3D)
• Whole bones or tissue
samples are immersed in POM
solution.
• Samples imaged and analyzed
with µ- or nanoCT.
• Simultaneous visualization of
bone, BMAT, and vessels in a
single dataset*
• Adapts existing CT
infrastructure and analysis
techniques
• Simple staining protocol
• Non-invasive
• Accurate measure of Ad.Dm
• High spatial and contrast
resolution needed to
discriminate blood vessel
network
• Not yet commercially available
• Not very sensitive for sparsely
BMAds
• Diffusion can take several days,
depending on the sample size
FIB-SEM
• Ultrastructure
• Cell-cell interactions
3D electron microscopy • Cellular and sub-cellular
resolution of BMAd
within niche
• Requires highly specialized
equipment
• Time-consuming
• Limited field of view
• High cost
*High-resolution µCT only (<2µm resolution). Ad.Dm, Adipocyte diameter; N.Ad, Adipocyte number; Ad.V, Adipocyte volume; BMAd, bone marrow adipocyte; BMAT, bone marrow
adipose tissue; FIB-SEM, Focused Ion Beam Scanning Electron Microscopy; POM, polyoxometalate; Ma.Ar, Marrow Area; µCT, micro-computed tomography.
IN VIVO IMAGING
While ex-vivo techniques provide ample information of
structures and allow for specific quantification of tissues, non-
invasive imaging tools are essential when it comes to clinical
studies so as to better understand the pathological processes that
affect the BM in situ. To date, magnetic resonance imaging (MRI)
is considered as the reference imaging modality to appraise in
vivo BMA (92, 93). This powerful imaging tool has been used
in animals, for example to follow the effects of zoledronic
acid treatment on marrow adipogenesis in ovariectomized
rats (47), to quantify the decrease in BMAT volume in obese
exercising mice (63), and to follow the progression of BMA in
murine hematopoietic recovery [(60, 61); Figures 3C,D]. Due
to their small size, such measurements are not straightforward
in rodents, as they require very strong magnetic fields for
meaningful BMA signal detection, and dual-energy µCT is a
valid alternative. MRI techniques are primarily applied in vivo in
humans (Figures 3A,B). Indeed, the growing interest in BMA in
relation with post-menopausal osteoporosis, fractures, metabolic
perturbations, as well as over- or undernutrition states, opens up
potential exciting perspectives for clinicians (94). However, the
multiple interfaces between trabecular bone and bone marrow
foster local magnetic inhomogeneities and challenge the accuracy
and precision of BMAT quantification.
What Can We Measure?
Main MR Imaging Biomarkers
The most relevant imaging biomarker used to quantitatively
assess BMAT using MRI is the proton-density fat fraction
(PDFF), which is the ratio of unconfounded fat signal to the
sum of the unconfounded fat and water signals [(92, 92, 95,
96); Table 5]. As a result, the main challenge and limitation
with quantitative BMAT assessment using MRI is to minimize
the confounding factors to measure only signals coming from
lipid protons. Interestingly, PDFF assessment of BMAT has
benefited from technical developments in abdominal imaging.
These technological improvements have been crucial for the
emergence of reliable and non-invasive approaches to quantify
adipose tissue in a standardized manner, especially through
single-voxel proton spectroscopy (1H-MRS) and chemical shift
encoding-based water-fat imaging (WFI) techniques (95).
The second most common quantitative parameter reported
in the literature reflects BMAT fatty acid composition. This
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FIGURE 3 | (A,B) Proton-density fat fraction (PDFF) maps generated using chemical shift encoding-based water-fat imaging from a commercially available sequence
on a 3 Tesla magnetic resonance scanner. Coronal oblique acquisition of the left hip (A) and sagittal acquisition of the lumbar spine (B) of a 69-year-old woman with
chronic lumbar and inguinal pain. Regions of interest can be drawn to assess bone marrow adiposity [(1) 94%, (2) 77%, (3) 71%, (4) 96%] at different anatomical sites
through the PDFF parameter. (C,D) A three-point Dixon acquisition using a spin-echo based sequence and chemical shift encoding-based water-fat separation was
conducted on a 9.4 Tesla horizontal magnet, to assess BMAT in vivo at the peak of aplasia after irradiation and bone marrow transplant in an 8-week-old C57BL6
female mice housed at room temperature fed ad libitum standard diet with antibiotics supplemented in the drinking water. The lower limb is shown as imaged in
maximal flexion (61). Normalized fat content map (C) and fat content overlaid a magnitude image, red 10% - yellow 100% (D) show high BMAT content in the distal
femur and also some BMAT in the proximal femur (horizontal, top of image) and throughout the tibia (diagonally across the image), in comparison to fat signal of
surrounding extramedullary adipose tissue.
specific evaluation is a topic of growing interest, as saturated fatty
acids may have deleterious effects on the osteoblast lineage and
may play a role in multiple inflammatory processes along with
certain polyunsaturated fatty acids, affecting bone health (97). Fat
composition assessment can be performed through an expression
of its degree of unsaturation or polyunsaturation, calculated,
respectively as the ratio of signal coming from the olefinic
protons at 5.31 ppm or diallylic protons at 2.8 ppm on 1H-MRS
acquisitions, to the sum of all lipid signals (Table 5), as discussed
in detail in section Single-Voxel Proton Spectroscopy (93).
Robustness of 1H-MRS and WFI Methodologies
When the main biases are taken into account, WFI sequences
appear to be robust in quantifying PDFF against changes in
experimental parameters, in good agreement with 1H-MRS [r =
0.979 reported by (98), and R2 = 0.92 by (99)], using calibration
constructs [BM phantoms: R2 = 0.97; (100)], and in agreement
with histology using excised lumbar vertebrae [r = 0.72;
(101)]. The intraclass correlation coefficients for repeatability
and reproducibility of WFI were, respectively 0.997 and 0.984
(102), and the coefficient of variation in the quantification of
PDFF varied from 0.69 to 1.70% (103). Moreover, a negative
correlation (r = −0.77; 77) was demonstrated between 1H-
MRS-based PDFF and ex vivo biomechanical vertebral properties
(failure load), highlighting the relevancy of this parameter in
bone strength (104). The reproducibility of 1H-MRS is known
to be excellent, especially when assessing the lumbar spine in
vivo, with an average coefficient of variation of vertebral bone
marrow content of 1.7% (93, 105). Although 1H-MRS has long
been considered the gold standard (105), WFI seems therefore to
be a relevant and efficient alternative due to its ability to derive
spatially resolved PDFF maps, with an absolute precision error
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TABLE 5 | Main quantitative parameters assessed when using in vivo imaging techniques to explore bone marrow adipose tissue.
Parameter Definition Properties Main imaging techniques Outcome
MRI- or
CT-based
techniques
Bone marrow fat
fraction (BMFF)
Estimate of relative bone
marrow fat content
• Generic term
• Sensitive to experimental
parameters when measured
with MRI
• Single-voxel proton spectroscopy
• Water-fat imaging
• Dual-energy CT
Marrow fat content
MRI-based
techniques
Signal fat fraction
(SFF)
Ratio of fat signal to the
sum of the fat and water
signals
• Generic term
• Specific to MRI techniques
• Can be sensitive to
MRI parameters
• Single-voxel proton spectroscopy
• Water-fat imaging
Proton-density fat
fraction (PDFF)
Ratio of unconfounded
fat signal to the sum of
the unconfounded fat
and water signals
• Unconfounded imaging
biomarker
• Insensitive to MRI parameters
• Single-voxel proton spectroscopy
• Water-fat imaging
Degree of lipid
unsaturation
Ratio of signal coming
from unsaturated lipids to
the sum of all lipid signals
• Olefinic protons (5.31 ppm) are
often used as an estimate of
unsaturated lipids
• Single-voxel proton spectroscopy Marrow fatty acid
composition
BMFF, bone marrow fat fraction; CT, computed tomography; MRI, magnetic resonance imaging; PDFF, proton density fat fraction; SFF, signal fat fraction.
of 1.7% between C3 and L5 vertebrae (106), and no significant
differences with spectroscopic assessment in children (99) or in
adults (98).
With regard to BMAT composition, although similar values
have been reported between measurements from high-resolution
proton spectroscopy acquisitions on ex vivo specimen and in
vivo imaging (R = 0.61; 71), the true BMAT unsaturation level
is consistently underestimated in in vivo acquisitions because of
the fewer visible peaks. As a result, Li et al. preferred the use
of pseudo-unsaturation level to better discriminate the apparent
BMAT composition assessment in in vivo studies from ex vivo
measurements. This differentiation in terminology reflects well
the need to bear in mind the technical limitations encountered
when evaluating fat composition in vivo.
Toward a Better Standardization of MRI
Techniques
Because 1H-MRS and WFI can be performed in most clinical
facilities, their main technical limitations must be taken into
account when assessing in vivo BMAT. A better standardization
of the methodologies used to quantitatively assess BMAT would
increase the accuracy of the reported PDFF in the literature, as
well as the relevancy of inter-study comparisons.
Single-Voxel Proton Spectroscopy
Based on the frequency shift which exists between molecular
groups, signals fromwater and lipid protons can be discriminated
in a defined voxel of interest through 1H-MRS. However,
although the area under each peak of the acquired spectrum is
related to the number of protons of a specific chemical moiety,
the MRS acquisition and post-processing analysis to calculate
PDFF needs to consider the following confounding effects.
First, the water and fat components of BMAT have different T2
relaxation times. Therefore, in the absence of any T2-correction,
the calculated signal fat fraction from 1H-MRS acquisitions is
T2-weighted, depends on sequence parameters and overestimates
the true PDFF. An 1H-MRS acquisition at different echo times
combined with a T2 correction can removed T2-weighting effects
(107, 108).
Second, even though initial 1H-MRS studies mainly
considered the methylene group peak at 1.3 ppm to calculate
bone marrow fat fraction or lipid/water ratio, adipose tissue has a
complex spectrummade of multiple peaks. An oversimplification
of the model used may reduce the accuracy of the qualitative
and quantitative fat assessment. However, the trabecular
microarchitecture promotes broad spectral peaks which make
peak fitting challenging (93). Nevertheless, constrained peak
fitting methodologies have been depicted and performed
successfully at the hip and lumbar spine (107, 108).
Third, the short T1 value of bone marrow fat compared to
water induces a relative amplification of the measured signal.
PDFF calculations might be subsequently biased if T1 effects
are not minimized. This effect can be minimized by using long
repetition times for 1H-MRS acquisitions (93, 95, 109, 110).
Finally, the choice of the sequence mode is also of importance
and depends on the employed echo times. By lowering J-coupling
effects and being able to acquire spectra using shorter echo
times, stimulated echo acquisition mode (STEAM) might offer a
more accurate precise BMAT quantification compared to point-
resolved spectroscopy (PRESS) sequences, despite its relatively
noisier sensitivity (93).
The consideration of the above confounding effects is critical
for assuring the robustness of MRS-based PDFF measurements
across imaging protocols and imaging platforms, and essential
toward the standardization of MRS-based PDFF measurements.
Water-Fat Imaging
Dedicated WFI techniques for BMAT assessment
WFI techniques share comparable confounding factors with 1H-
MRS: there is a need for T
∗
2 decay correction and T1 bias
minimization, as well as a consideration of the multi-peak
spectral characteristics of fat.
Indeed, due to the complex bone microarchitecture, the
multiple interfaces between trabeculae and bone marrow induce
an important but differential T∗2-shortening effect affecting both
water and fat. T∗2 decay effects have therefore to be considered
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in the estimation of PDFF based on WFI. Despite its theoretical
justification, a dual-T∗2 decay correction adjusting both water and
fat relaxation times provides accurate bone marrow fat fractions
at a nominal fat fraction close to 50% but noisy PDFF maps
were reported in the spine in regions with lower values (104).
Therefore, a single T2∗ decay model should be at least adopted
in BMATWFI (93).
Regarding the T1-effect, the relative signal amplification can
be easily lessened by using low flip angles or predetermined
calibration values on WFI acquisitions (93, 95, 109, 110).
Finally, concerning the multi-peak spectral characteristics
of fat, one direct consequence in WFI that illustrates an
oversimplification of the model used is the “grayish” appearance
of adipose tissues on water-only images generated from WFI
reconstructions considering a single fat peak. This residual fatty
signal may come from an incomplete discrimination of fat and
water signals, especially between olefinic fat protons and water
(111). Although this simplification is acceptable for most clinical
applications, a more advanced modeling of the fat spectrum is
necessary for a quantitative purpose.
Commercially available WFI solutions
As mentioned above, the methodological improvements of fat
quantification using MRI emerged mainly from abdominal
imaging. Most MRI vendors have played an active role in the
development of these sequences. Although these commercial
quantitative WFI solutions aim to quantify liver PDFF, these
techniques may be an easier and interesting alternative to 1H-
MRS in quantifying BMAT. An approximation with the multi-
peak liver fat spectrum can indeed be considered, as only a
negligible difference between the total signal fat from the 3 main
peaks was reported when comparing the proximal femoral bone
marrow and the liver (87 vs. 90%, respectively) (93, 107, 112).
In addition, these sequences implement de facto a T∗2 decay
correction, and because the T1-effect can be simply lowered
through a low flip angle, these solutions might be performed for
BMAT PDFF assessment.
Other Technical Considerations
Other confounding factors may also be taken into account,
such as noise-related bias (especially when using complex-
based methods), eddy currents effects, gradient timing mis-
registrations, phase errors in WFI and correction of J-coupling
effects and chemical shift displacement effects in 1H-MRS
(99, 107, 110). Their description goes beyond the purpose of
this review, but they are fundamental for the development of
future techniques.
Current Challenges When Imaging In Vivo
BMAT
A More Accurate Description of BMAT Fatty Acid
Composition
Reporting of BMAT fatty acid composition through an
expression of its degree of unsaturation constitutes the second
most common quantitative parameter provided in the literature
after PDFF-based quantification of total BMAT. Currently, only
1H-MRS can reliably assess BMAT composition.
However, contrary to PDFF assessment, there is not sufficient
literature on the methodological considerations that should
be followed in imaging studies. The importance of STEAM
acquisitions over PRESS when assessing BMAT composition
has been nevertheless highlighted, as a low reproducibility of
unsaturation level measurements has been reported using the
latter, with a reported coefficient of variation of 10.7% (105).
Moreover, the proximity and partial overlap of the olefinic
peak with the water peak (present at 4.7 ppm) reduce the
robustness of the peak fitting process. As a result, in addition
to the previously described technical considerations, post-
processing the spectra for this specific purpose is challenging,
especially in young adults. Areas with low fat content, more
frequently encountered in red bone marrow, limits the accuracy
and precision of the reported measurements (93). The extraction
of BMAT unsaturation levels is subsequently less prone to
variations in yellow bone marrow or red marrow with elevated
fat content.
Consequently, there is an urge to standardize and improve
the reliability of this potential biomarker, as the degree of
unsaturation of BMAT might have clinical implications, such as
its potential role in the occurrence of fragility fractures (113, 114).
A Better Depiction of Physiological Values
To date, studies performed in healthy subjects have allowed
for the description of physiological variations, especially in
the spine. In children, WFI showed a decrease in PDFF
measurements from the lumbar to the cervical spine, with a
natural logarithmic increase with age but without sex difference
(99). However, in adults, sex-related variations in addition
to age-dependence of PDFF have been reported in the spine
(106, 108). Regarding BMAT composition, differences in the
degree of saturation have also been observed between adult
males and females, with unsaturated lipids being higher in
women (115).
Nonetheless, even though these physiological variations are
critical for a better understanding of BMAT physiology, data
is still insufficient in the literature to determine the exact
normal values by age and gender, primarily due to the lack of
standardization in methods used to assess BMAT.
Alternatives to 1H-MRS and WFI
Diffusion weighted-imaging, relaxometry, texture analysis, direct
signal intensity, and dynamic contrast-enhanced imaging are
alternative tools that have been performed to assess bone marrow
adiposity. Although they provide interesting information, such
as functional parameters related to bone marrow vascularization
(116), theseMRI techniques have not yet reached a consensus due
to the insufficient number of relevant publications.
On the contrary, dual-energy computed tomography
(DECT) is an emergent technique which may become a
powerful alternative to MRI techniques as it can provide
quantitative parameters representing both mineral and organic
bone components (117). Consequently, whereas conventional
single-energy quantitative computed tomography methods
underestimate volumetric BMD measurements, DECT can
correct for BMAT, resulting in more accurate densitometric
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measurements (118–120). Furthermore, BMAT content can be
explored reliably, as good correlations have been reported with
WFI and histology on cadavers (121, 122), and 1H-MRS in vivo
(123). Potential interesting applications exist in oncology, to
follow marrow fat expansion and BMD involution in patients
after chemotherapy or radiotherapy (124). The main limitations
of this modality are the radiation exposure, the need for
prior phantom calibration, and the lack of standardization
and data regarding reproducibility between different scanners
and manufacturers.
In summary, MRI constitutes the current gold standard for in
vivo imaging of BMAT in a clinical research setting, with current
acquisition methods allowing for inter-center comparability. The
field would however benefit from increased standardization,
both in terms of reporting of confounding factors of the
measured subjects as recommended in Table 1 and in terms of
definition of standard sites of measurements, in order to increase
comparability and to establish physiological reference ranges in
humans and possibly larger mammals. The use of MRI for mouse
models is only starting, due to the need for very strong magnetic
fields for meaningful BMA signal detection; dual-energy µCT is
a valid alternative for murine in vivo imaging.
FROM CELL ISOLATION TO IN VITRO
MODULATION
BMAds exist in a complex microenvironment within the bone,
embedded within the marrow tissue where access to live cells
for functional analysis is not trivial. Complementary to the
above discussed challenges associated to BMAd imaging within
their native environment, in vitro systems and ex vivo assays
are crucial for understanding of the BMAd and its subtypes
at the cellular level. The difficulty in isolating and handling
primary mature adipocytes from the BM has led to the use
of in vitro adipogenic differentiation assays from BM stromal
cells as a surrogate method to study BMAd, an approach widely
used in the field of peripheral adipocyte biology. This approach
relies on the isolation of a stromal vascular fraction (SVF) from
adipose tissue which is then plated and expanded in tissue
culture plastic. The resulting adherent monolayer of stromal cells
isolated from the BM, the so-called BMSC fraction, acquires
the phenotype of multilocular and sometimes fully mature
unilocular adipocytes in the presence of specific differentiation
cocktails in standard 2D cultures. Mature BMAds, which in
vivo develop only after birth (125), most likely originate from
a specific subset of progenitor cells present within the BMSC
fraction. This biological sequence thus supports, in part, the
use of differentiated BMSCs to model BM adipogenesis. In vitro
differentiation assays, however, reveal a cellular response to
chemical stimuli resulting in a sum of specific phenotypes which
describe in vitro plasticity, but do not necessarily reflect their
native in vivo differentiation potential. The in vitro plasticity of
BMSCs is in fact often larger than the plasticity revealed by in vivo
readouts in native or injury-repair conditions, highlighting the
importance of complementary in vitro assays and in vivo readouts
to establish cell fate mapping within the BM, as described below
and extensively reviewed elsewhere (126, 127). The sections
below summarize key challenges and practical considerations to
minimize variability and increase comparability in future BMAT
cell-based studies, whether based on the isolation of primary
BMAds or in vitro adipogenesis from BMSCs.
BMAT: Location and Isolation
The BM is a soft tissue within the medullary cavity of compact
bone. A mixture of hematopoietic precursors and differentiated
cells, adipocytic cells, stromal cells, blood vessels, and nerve
fibers occupy the marrow space within a complex network of
extracellular matrix. Several techniques to isolate BMAT have
been developed, all of which require invasive procedures to
extract different populations from the encompassing bone.
In juvenile (age 8 to 12-week-old) mice, yellow/adipocytic
marrow is present essentially in the distal tibia (filling up about
one third of the total shaft length), the tail vertebrae and phalanx.
Of the mouse strains systematically compared, BMAT is maximal
in these locations in C3H/HeJ mice, and minimal in C57BL6/J
mice (12). Older mice show a progressive increase in BMAT from
distal to proximal, gradually gaining mature adipocytes in most
skeletal sites of red/hematopoietic marrow. BMAT development
and progression varies with strain and gender (128). Sites of
murine BMAT for isolation in steady-state are thus small, and
obtaining sufficient number of cells for cell sorting or cell
culture purposes requires in most cases pooling samples from
several animals.
It is important to note, as discussed in the in vivomodulation
and in vivo tracing sections, that there may be differences in
developmental origin according to the site of BMAT isolation.
Due to the high degree of yellow/adipocytic marrow in the
distal tibia, which also contains less trabecular bone than
the caudal vertebrae, isolation of intact BMAT is relatively
straightforward from the tibia after section at the epiphyses
followed by gentle flushing or centrifugation. Contrarily,
enzymatic digestion or mechanical disruption provides a higher
yield of primary adipocytes from the tail due to the high
number of caudal vertebrae and the predictable yellow/adipocytic
marrow transition in the murine tail from the non-weight
bearing segments. It is particularly important to note, however,
that the fibrous tissue surrounding tail vertebrae is very
rich in subcutaneous and periosteal adipocytes which require
extensive mechanical removal or enzymatic digestion prior to
isolation of BMAds to avoid contamination from subcutaneous
adipocytes. One should also be aware that crushing bones
can result in high cell death of BMAds and BMSCs, and it
is thus to be avoided. Extraction of the intact BM plug or
gentle mechanical disruption of the bone by fragmentation
with a scalpel or scissors is thus preferred. Alternatively, a
disrupted marrow plug can be obtained from smaller bones
by removing the epiphysis and placing the open shaft in
a PCR tube with a pierced bottom inside an Eppendorf
tube containing a small amount of media (e.g., 200 µl),
then gently centrifuging (e.g., 1 s at 500 g). BMAd markers
are present in the top buoyant layer, while hematopoietic
markers are only present in the pellet fraction upon RNA
transcription analysis.
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The long bones of mice are of similar size than human
iliac crest biopsies, also called trephine biopsies, which involve
the spongy bone and are performed for diagnostic purposes in
hematology (1–2 cm long and 0.2–0.4 cm in diameter). Isolation
and mounting approaches are thus often appropriate for both
murine and human samples. Bone marrow aspirates are in most
instances performed in parallel to trephine biopsies. In pediatric
practice, BM aspirates are often performed from the sternum.
Either are excellent sources of BMAT for research purposes
after appropriate ethical approval. Debris from hip- or knee-
replacement surgeries, including limb amputations, as well as
spine neurosurgery also provide material rich in BMAds, as these
are skeletal sites of abundant yellow/adipocytic marrow in the
human adult.
Due to physiological BMAT specific variations according
to species, strain, age, gender and skeletal site, as well as
variations imposed by the isolation technique (flushing, spin-
down, direct collagenase digestion, other enzymatic digestion), it
is extremely important that researchers detail these parameters
and indicate yield of primary BMAds or BMSC populations
to favor comparisons across groups. Future efforts of the field
should include evidence-based recommendations on extraction
protocols that best preserve the heterogeneity of BMAd and
their precursors. Other factors that may influence BMAT quality,
and therefore yield, are related to body weight, bone weight
or length and presence of metabolic perturbations or disease.
BMAT obtained from human samples may be normalized to
weight (µg) of tissue. Weight-based normalization remains
however challenging for the small murine samples, where
normalization per bone or “per leg” (e.g., tibia and femur) is
standard (129).
Mature BMAds: Isolation and Culture
Isolation of primary mature BMAds has been done to
high purity by multiple gentle centrifugation steps (9, 56,
130, 131) and may include enzymatic digestion to aid
dissociation of BMAds from their surrounding connective
tissue. BMAds, just like visceral adipocytes, are fragile cells
that are very sensitive to the strains of handling and
temperature gradients. Samples must be manipulated gently
and typically at 17–37◦C to avoid lipid droplets from bursting.
Generally, BMAd numbers obtained from murine bones are
low due to the small volumes and their affinity to plastic
and proneness to floatation or bursting, which encumbers
handling. Cell counting of mature adipocytes by hemocytometer
or flow cytometry is not representative of the sample at
hand, and quality controls for purity and viability need to
be devised through other methods including, for example,
immunofluorescence for adipocyte yield and quantification
of hematopoietic cell contamination (e.g., DAPI, phalloidin,
LipidTox-DR and anti-CD45) or nuclei counting coupled to
ceiling culture for quantification of yield of viable mature
adipocytes. For claims on purified BMAds, especially those
that refer to population based transcriptional analysis or
proteomics/lipidomics, it is paramount that researchers specify
the degree of hematopoietic and undifferentiated BMA cell
contamination in both mouse and human BMAT. Single cell
RNA sequencing techniques will facilitate BMAT studies, albeit
at a high cost.
The possibility of fluorescence activated cell sorting (FACS)-
based purification of mature adipocytes for downstream studies
has been recently described for extramedullary adipocytes, based
on forward/side scatter light signal and viability ensured by
manual adjustments to the sorting pressure (132). It is to be
demonstrated whether this approach may be compatible with
primary BMAd isolation.
Regardless of the isolation approach, a large number of
primary BMAds must be initially isolated for most downstream
assays (see section on BMAd assessment in vitro). On successful
isolation of mature BMAds, their culture is delicate and short-
lived. Ceiling culture in 2D allows for maintenance of BMAds
for about 1 week (Figure 4E), after which de-lipidation is often
observed. To avoid de-lipidation, irradiation of the cells has
proven to be technically beneficial prior to culture (9). The
recent description of protective 3D BMAd cultures in engineered
devices or silk scaffolds holds great promise to recapitulate
important clues for their behavior in vivo (133–135), but raises
new challenges to develop efficient cell extraction protocols for
endpoint analysis and 3D imaging techniques compatible with
these set-ups.
BMAd Progenitors: Isolation, Culture, and
Modulation in vitro
Mature BMAds coexist hand-in-hand with their immature
progenitors, which constitute a subset of the total BMSC
fraction. The BMSC fraction has been defined by either
(i) exclusion of endothelial and hematopoietic markers
[typically CD31 to exclude endothelial components, CD45
to exclude hematopoietic components, and either murine
Ter119 or human Glycophorine A to exclude nucleated
erythroid lineage cells which lost CD45 expression, as
discussed in Boulais et al. (136)], or (ii) by adherence and
expansion in tissue culture plastic. Specific subpopulations
with functionally validated in vivo stem cell or progenitor
function, the so-called skeletal stem cells (SSCs) and their
downstream committed or partially committed stromal,
bone and cartilage progenitors have been recently described
in mouse and human BM (137, 138). They present in
vitro adipogenic potential and different degrees of in
vivo adipogenesis, with human CD146 constituting the
best functionally characterized marker for prospective
isolation of SSCs (139, 140). Other skeletal multi-potent
populations have been identified within the BM, including
PαS (CD45−Ter119−PDGFRα+Sca1+) (141, 142), although
care must be taken when defining clonal multi-potency
(125, 140). Specific markers to prospectively isolate intermediate
steps within the stromal to adipocyte commitment axis
have also recently been identified in mice by Ambrosi et al.
Namely, a tri-potent bone/cartilage/adipocytic perivascular
CD45−CD31−Sca1+CD24+ stem-cell like population,
a CD45−CD31−Sca1+CD24− adipocytic progenitor
population and a more mature CD45−CD31−Sca1−Zfp423+
BMAd precursor population were identified in the
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FIGURE 4 | In vitro bone marrow adipocyte differentiation. (A) Bright field image (objective 10x) of OP9 cells differentiated in presence of serum, dexamethasone,
insulin and IBMX (DMI cocktail) for 6 days, (B) Digital Holographic Microscopy (DHM) image of OP9 cells differentiated in DMI for 7 days. (C,D) Primary murine bone
marrow stromal cells after in vitro differentiation in similar conditions imaged by light-transmission microscopy, where lipid droplets show a high refractive index (C) or
stained with neutral lipid oil-soluble colorant Oil Red O (D). (E,F) Primary murine BMAds from 2-month-old FVB female mice as seen by light-transmission microscopy
(E) or stained with Oil Red O (F).
context of aging, high-fat diet (HFD) induced obesity
and bone regeneration (5). No equivalent adipocytic
differentiation hierarchy has yet been described in the
human BM.
Due to the difficulty in isolating and expanding highly purified
BMAd progenitors in mice, and to the lack of specific prospective
BMAd progenitor markers in human BM, most studies to date
have used unfractionated murine BMSCs, or in vitro expanded
human BMSCs complying with International Society for Cellular
Therapy (ISCT) standards (143) to produce in vitro differentiated
BMAds for functional studies. ISCT standards provide a minimal
set of surface markers and functional assays to validate human
BMSC homogeneity. Standardized downstream functional assays
have been proposed by the FDA (144–146). BMSC cultures rely
on the rapid adherence of the cells to the culture dish, which
allows exclusion of most hematopoietic cells from the culture.
Nonetheless, passaging and sometimes sorting is necessary to
eliminate macrophage contamination. As for primary isolated
BMAds and to maximize comparability across studies, it is
paramount to detail the source of BMSCs (gender, age, strain if
applicable, metabolic diseases, skeletal location) and the method
of isolation, such as specific enzymatic (e.g., collagenase-1,-2,-
4, a combination thereof, trypsin) or mechanical dissociation
as well as the specific expansion protocol, whose heterogeneity
may explain some disparities in the field (summarized in Table 6,
BMAS reporting guidelines as summarized in Table 1) (162). It
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TABLE 6 | Variability in murine bone marrow stromal cell isolation protocols.
Samples Isolation medium RBC lysis Enzymatic digestion Depletion/
enrichment
Application References
Flushed
BM
DMEM/F12, 20% FBS,
P/S, 2mM L-glutamine,
0.1mM NEAA, 3mM
sodium pyruvate
– – – Cell culture (147)
PBS, 2%FBS, 2mM EDTA – 3 mg/ml col. I
+ 4 mg/ml Dispase
(15min 37◦C)
– Cell culture (148)
Leibovitz’s L-15 medium, 1
mg/ml BSA, 10mM
HEPES, 1% P/S
0.8%
NH4Cl
0.005% trypsin + 0.002%
EDTA + 0.25 mg/ml col.
IV (4min 37◦C)
Anti-CD45,
Nestin-GFP+
FACS
Flow
cytometry
(149)
HBSS, 2%FBS – DNase I + col. IV or +
liberaseDL (15 or 20min
37◦C)
– Flow
cytometry
(27, 150)
DMEM, 15% FBS, 2mM
L-Glutamine, 1% P/S, 3.7
g/l NaHCO3
– – – Cell culture (151)
α-MEM, 10% FBS, 1% P/S – – – Cell culture (152)
α-MEM, 15% FBS, 1%
P/S, 2.2/l NaHCO3
– – – Cell culture (153)
α-MEM – – – Cell culture (154, 155)
RPMI-1640, 10% FBS, 1%
P/S
– – – Cell culture (156)
- - Trypsin (2min 37◦C) – Cell culture (84)
Long term medium – – – Cell culture (157)
RPMI-1640, 20% FBS,
2mM glutamine, 1% P/S
– – – Cell culture (158)
Centrifuged
BM
N/A RBC lysis
buffer
– – BMAd
isolation
(56)
N/A – – – Cell culture (135, 159)
Crushed
long bones
PBS – col. (20min 37◦C) – Flow
cytometry
(28)
Flushed
and cut
long bones
α-MEM, 10% FBS – 1 mg/ml col. II (1–2 h
37◦C)
– Cell culture (160)
Cut and
washed
long bones
DMEM H2O 6s 0.2% col. (1 h 37
◦C) – Flow
cytometry
(141)
N/A – 5% col. Anti-CD45,
anti-Ter119,
anti-CD31
Cell
Culture
(161)
Cut long
bones
PBS, 20% FBS ACK 0.5% col. II (1 h 37◦C) – Flow
cytometry
(5)
BSA, bovine serum albumin; Col., collagenase; DMEM, dulbeco’s modified eagle medium; FBS, fetal bovine serum; RBC, red blood cell; RPMI, L-glutamine, phenol red, reduced serum;
P/S, penicillin/streptomycin; NEAA, non-essential amino acids.
is equally important to include quantification of contamination
with hematopoietic or endothelial cells, and, specifically for
BMSC populations, and to quantify the overall progenitor
function of the primary isolate through fibroblastic colony
forming unit assays (CFU-F) prior to adipocytic differentiation.
Induction of adipogenesis from BMSCs in vitro has included
a variety of inducers in standard 2D culture conditions, as
summarized for primary murine samples in Table 7. Most
differentiation techniques are based on methods developed for
murine extramedullary pre/adipocytes (e.g., 3T3L1) or BMSCs
primed for adipogenic differentiation (such as C3H10T1/2, 3T3-
L1, or OP9). The common denominator includes a combination
of the corticosteroid dexamethasone, which ultimately induces
master transcriptional regulator of adipogenesis C/EBP-α,
and phosphodiesterase inhibitor isobutylmethylxanthine
(IBMX), which leads to cAMP accumulation, protein kinase
A activation and thus PPAR-γ expression. The cocktail is
classically accompanied by insulin exposure, whether from
the serum or exogenously administered. Thus the acronym
“DMI” cocktail for Dexamethasone, IBMX and insulin (163).
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TABLE 7 | Variability of in vitro murine bone marrow stromal cell adipogenic differentiation protocols.
References (147) (84) (156) (160) (56) (135) (5)
Maintenance
Medium DMEM:F12 α-MEM RPMI α-MEM α-MEM or DMEM 60% DMEM low Glc: 40%MCDB
Serum 20% FBS 10% FBS 10% FBS 10% FBS 20% or 10% FBS 2% FBS
Other 0.1mM NEAA 200µM NEAA ITS, linoleic acid, dexa, AA, EGF,
LIF, PDGFBB, bFGF
Adipogenic
Medium DMEM:F12 α-MEM DMEM α-MEM α-MEM or DMEM 60% DMEM low Glc: 40%MCDB
Serum 20% FBS 10% FBS 9% horse
serum
10% FBS 20% or 10% FBS 2% FBS
Other 200µM NEAA
IBMX (µM) 500 500 450 0.5 500 0.5
Dexa or
Hydrocortisone (µM)
1 0.5 0.25 1 1 1
Indomethacin (µM) 100 60 50
Insulin (µg/ml) 5 5 0.01 10 10 10 5 5
Rosiglitazone (µM) 1 1 1
T3 (nM) 1 1
Differentiation time 2 weeks 3 weeks 12 days 2 weeks 2–4 days 3–4 days 4 days 48 h 5 days
NEAA, non-essential amino acids; dexa, dexamethasone; ITS, insulin-transferrin-selenium mix; AA, L-ascorbic acid 2-phosphate; EGF, epidermal growth factor; LIF, leukemia inhibitory
factor; PDGFBB, platelet-derived growth factor BB; bFGF, basic fibroblast growth factor; FBS, fetal bovine serum.
In addition, adipogenesis can be further boosted through
the use of cyclooxygenase-2 (COX) inhibitor indomethacin
or PPAR-γ agonist rosiglitazone. Of note, the mechanical
properties of the substrate are also determinant for BMSC
differentiation, and even dominant to exogenous biochemical
signaling (164), with softer matrixes favoring adipogenesis. The
role of extracellular matrix components in this context, and its
rate of degradation, has been however largely understudied in
this context.
BMAd Differentiation Assessment: In Vitro
Assays and Applications
Multiple different cell types have the ability to accumulate lipid
droplets, and thus we must evaluate the criteria with which we
distinguish BMAds from other cells of the BM. In the context
of extramedullary stromal differentiation, some groups have
adopted the criteria of presence of at least four lipid droplets
to define an adipocyte (165). This is especially useful as a
threshold in imaging techniques where lipid droplets are visible
(Figures 4A,C,E). As such, each investigator should critically
evaluate what threshold is used as a definition.
Adipocytic differentiation is not completely efficient from
primary BMSCs obtained on isolation, and the heterogeneity in
cultures is well-known (166). This may be due to undetected
heterogeneity of the initial BMSC population and adipocyte
progenitors therein, to paracrine signaling cues in the culture,
or, possibly, to presence of stromal cells that actively inhibit
adipogenesis as recently described for CD142+ SVF cells
in murine extramedullary adipogenesis (167). Moreover, as
discussed above, in vitro differentiation potential may not
faithfully reflect in vivo potential. Stringent in vivo assays in the
form of heterotopic marrow formation by in vivo transplant in
permissive conditions should thus be the norm to reveal the
true lineage potential (140, 168, 169). Researchers must therefore
rely on genetically modified mouse models with differential
donor/recipient marker expression, or, in the case of human
samples, in xenotransplants into immune-deficient mice with
species-specific surface marker, Alu sequence or mitochondrial
DNA detection to determine donor vs. host BMAds.
Upon isolation and culture or differentiation in vitro,
assessment of BMAd maturation relies on the definition of
the BMSC-to-BMAd axis and on established or forthcoming
readouts. Classical biochemical techniques (including western
blot, real-time qPCR, flow cytometry, RNA sequencing,
lipidomics) require relatively large cell numbers, thereby
limiting assay performance for BMAds. Importantly, the cells
on each extreme of the maturation spectrum vary greatly,
as simply illustrated by the morphological changes when
comparing the spindle-shaped BMSCs with large lipid-filled
BMAds (Figure 4). This must be accounted for in the selection
of suitable references, such as reference genes for RT-qPCR
that do not change upon adipocytic differentiation. Thus,
cytoskeletal or metabolic genes must strictly be avoided as
reference genes, while at least two early/mid- (PPARγ, CEBPα)
and two late- (AdipoQ, Glut4, FABP4, LPL, PLIN1) stage
markers should be quantified as genes of interest to cover the
adipocytic maturation spectrum. The stability of reference
genes needs to be demonstrated upon differentiation in
every experimental setting, but others have identified good
reference gene in the context of adipocytic differentiation
from peripheral stromal cultures human and rodent studies
(170, 171).
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In vitro microscopy-based readouts classically detect lipid
droplet formation with fluorescent dyes (e.g., Nile Red, ORO,
BODIPY) (Figure 4F), or use of cells from fluorescently-tagged
reporter mice (e.g., tdTomato, RFP, GFP as extensively reviewed
in section in vivo Lineage Tracing). Whether for microscopy
or flow cytometric applications, careful interpretation of results
is required, as most mature BMAds will be lost on liquid
handling, and care must be taken not to count lipid vacuoles
from broken cells as BMAds. More recently, label-free techniques
such as digital holographic microscopy (Figure 4B) or Raman-
based microspectroscopy have been developed for in vitro
BMAd cultures with high resolution and potentially improved
performance over classical techniques (172, 173). By preventing
staining and liquid-handling biases, these methods provide
additional information on lipid content along with quantification
of morphological parameters. Additionally, microspectroscopy
holds the promise to reveal information on chemical composition
at the single cell level, which may reveal physiologically
relevant heterogeneity.
Challenges in Cell-Based Assays
Isolation of primary BMAds remains challenging in both mouse
and human. In vitro BMSC or BMAd precursor differentiation
provides a valid alternative for studying the role of BMAds
in cell-based assays, although potential differences with in vivo
differentiated BMAds should always be acknowledged. This
presents a challenge for normalization with age-matched control
groups where the BMAds do not undergo similar changes. For
appropriate normalization, it is thus important to account for
both cell number and tissue weight, with pooling of control
group mice to reach similar levels of BMAd isolation from the
experimental and control groups for appropriate comparisons.
For both primary BMAds and BMSCs, the cell mixtures obtained
are highly dependent on the source and handling, and thus
gender, age, skeletal location, metabolic perturbations, as well-
extraction and culture methods should be thoroughly described
as detailed in the recommended BMAS reporting guidelines
(Table 1). With the application of in vivo BMA induction
protocols (reviewed in Tables 8, 9), BMAds are modulated
in cell size, number, and phenotypic/functional properties.
Additionally, measures of BMAd purity and BMSC CFU-F
progenitor function should be reported to increase comparability
of results across different researchers. It is imperative that as
the BMA field matures, so must the publication of consensus
protocols as well as definitions for both BMAd and BMSC
isolation and differentiation.
IN VIVO BMAT MODULATION
In Vivo Lineage Tracing
It is now well-accepted that BMAds differentiate from a small
number of radioresistant mesenchymal progenitor cells that
reside in the bone marrow. The ability to identify these
early progenitor cells, more mature precursor cells, mature
marrow adipocytes, and other mesenchymal lineage derived
cells (e.g., osteoblasts), has been accomplished by the advent of
TABLE 8 | In vivo modulation of bone marrow adipose tissue by dietary and
environmental factors.
In vivo
environmental
intervention
Animal model Outcomes
(assay)
References
High fat diet
(45–60%)
C57BL/6J mice ↑BMAT
↔or ↓
Bone mass
(O, µCT)
(174)
(175)
(161)
Physical exercise
(voluntary exercise
wheel in NCD and
HFD mice)
C57BL/6 mice ↓BMAT
volume in
NCD and
HDF-
fed mice.
↑Bone mass
(O, µCT)
(176)
(63)
Caloric restriction
(CR)
C57BL/6J mice (CR:
30% of NCD)
New Zealand White
rabbits [CR:
Moderate (30%) or
extensive (50–70%)]
↑ BMA
volume
(H, MR)
↑BMAT volume
(O, µCT, H)
(35)
(177)
Acute fasting (48 h) Sprague-Dawley
rats
BMAd size:
↓proximal
tibia
↔tail vertebrae
(O, µCT)
(178)
Cold exposure (4◦C) C57BL/6J
C3H/He
↓rBMAT
↔ cBMAT
(O, µCT)
(12)
CLA +FO
supplementation
C57BL/6 mice ↓BMAT
(H)
(179)
Dietary methionine
restriction
C57BL/6J mice ↑BMAT
(O, µCT)
(180)
↓, Decrease; ↑, Increase;↔, No change; BW, body weight; CLA, conjugated linoleic acid;
FO, fish oil; HFD, high fat diet; O, osmium tetroxide staining; BMAT, bone marrow adipose
tissue; NCD, normal chow diet; rBMAT, regulated BMAT; cBMAT, constitutive BMAT;
BMAd, bone marrow adipocyte.
modern lineage tracing using relatively specific Cre-drivers and
fluorescent reporters (5, 84, 137, 199–202). This approach has
the added benefit of being able to compare marrow adipocytes to
white, brown, and beige adipocytes, and adipocytes in different
anatomical locations in vivo.
Today’s lineage tracing consistently depends on the Cre/Lox
system (203). In the standard Cre/Lox system, Cre recombinase
is expressed under the control of a tissue-specific promoter to
permanently activate a reporter gene that functions to mark the
original Cre-expressing cell population and all daughter cells
that develop. Therefore, it is paramount that one has a detailed
understanding of the Cre driver’s spatiotemporal expression.
Lack of this understanding can result in false interpretations
of the origin of the cells. As an example, PdgfRα-cre traces
all the adipocytes in white adipose tissue, but within the
bone marrow, it traces about 50% of the adipocytes (202). By
contrast, Prx-1-cre traces all marrow adipocytes (202). It also
traces posterior subcutaneous white adipose tissue, including
beige adipocyte precursors, as the mesenchymal origin of this
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TABLE 9 | In vivo modulation of bone marrow adipose tissue by hormonal and pharmacological treatments in animal models.
In vivo intervention Animal model (route of administration) Outcomes (assays) References
Leptin ob/ob mice
(s.c. osmotic pumps)
↓ BMAT volume, ↑ bone formation
(H-t)
(181)
Type 1 Diabetic mice
(s.c. osmotic pumps)
↓ Adipocyte number,↔ bone mass loss
(H, µCT)
(182)
C57BL/6J mice
(s.c.)
↓ BMAT formation induced by CR,↔ BMD
(O, µCT, H)
(183)
Sprague-Dawley rats
(VMH injection)
↓ number of BMAT adipocytes
(H-t)
(184)
ob/ob mice
(rAAV-Lep, i.c.v.)
↓ BMAT, ↑ bone formation
(H-f)
(185)
Orchidectomy C57BL/6J mice ↑ BMAT
(H-f)
(152)
PPARγ Agonists
Rosiglitazone
Ovariectomy (OVX)
OVX + Rosiglitazone
Wistar rats (gavage) ↔ Ad.A./M.A., ↑ Ad.A./M.A., ↑ Ad.A./M.A.
(H-t)
(186)
Troglitazone ApoE−/− mice
(mixed with diet)
↑ BMAT (Ad.A./M.A.)
(H-t)
(187)
Rosiglitazone C57BL/6J mice
C57BL/6J mice + Exercise
C57BL/6J mice
C3H/HeJ mice
DBA/2J mice
A/J mice
Diabetic yellow agouti Avy/a
Ocn-Wnt10b mice
(mixed with diet)
C57BL/6J: ↑ BMAT (adipocyte number) (H-t)
Exercise: ↓ BMAT-induced by rosiglitazone (O,
µCT)
C57BL/6J: ↑↑ BMAT (H-f)
C3H/HeJ: ↑ BMAT (H-f)
DBA/2J:↔ BMAT (H-f)
A/J:↔ BMAT (H-f)
↑ BAT/WAT gene expression in marrow of
C57BL/6 mice, not increase BAT genes in
diabetic mice (H-t, RT-PCR)
↓ BMAT vs. WT (O, µCT)
(188)
(189)
(190)
(7)
(191)
PPARγ Antagonists
Bisphenol A Diglycidil Ether,
BADGE (partial
antagonist properties)
BALB/c (streptozotocin-induced diabetes)
male C57BL/6J mice
C57BL/6J mice + lethal irradiation
C57BL/6J mice + cytarabine
C57BL/6J mice + high fat diet (35%)
(i.p)
↓ BMAT,↔ BMD
↓ BMAT, ↑ BMD
↓ BMAT, ↑ hematopoietic recovery
↔ BMAT, rescue BMD
(H-t, µCT, IF, RT-PCR)
(192)
(37)
(193)
(194)
(195)
GW9662 (pure antagonist) C57BL/6 into C.B10-immune BM aplasia
(i.p.)
↓ BMAT, ↑ hematopoietic recovery
(IF, RT-PCR)
(196)
B-3 Adrenergic agonists
Isoproterenol or CL316,243
Sprague-Dawley rats
(i.p.)
C3H/HeJ mice
(i.p.)
BMAT from distal tibia and tail vertebrae resists
β-adrenergic-induced lipolysis
Moderate lipid droplet remodeling of BMAT
adipocytes (proximal tibia); (O, µCT, IHC)
(178)
Dexamethasone C57BL/6J mice
(i.p.)
↑ BMAT, ↓BMD
(H-f, µCT)
(197)
Lethal irradiation + BM
Transplantation
FVB
C57BL/6J mice
↑ BMAT
↔ BMAT, ↑ BMD in “fatless” FVB.A-ZIP/F
(H-f, µCT)
↑ M.Ad./M.A.
↑ Ad. number and size
(MQ-t, f,st,sp & MRI-f)
(193)
(61)
Beagle dogs ↑ BMAT
(H-t, hu, r)
(198)
Cytarabine (ARAC) Ablative
chemotherapy
C57BL/6J mice ↑ BMAT; (H-t) (194)
↓, Decrease; ↑, Increase; ↔, No change; BAT, brown adipose tissue; BMAT, bone marrow adipose tissue; BMD, bone mineral density; f, femur; H, histomorphometry; hu, humerus;
IF, immunofluorescence; IHC, immunohistochemistry; i.p., intraperitoneal; O, Osmium tetroxide staining; r, radius; st, sternum; sp, spine; t, tibia; WAT, white adipose tissue; rAAV-Lep,
recombinant adeno-associated virus (rAAV)-Leptin; BADGE, Bisphenol A Diglycidyl Ether; BM, bone marrow; CR, calorie restriction; Ad.A., adipocyte area; M.A., marrow area; PPARγ,
µCT, micro-computed tomography; RTPCR, real-time quantitative polymerase chain reaction; OVX, ovariectomy; VMH, Ventromedial Hypothalamus; WT, wild-type; s.c., subcutaneous;
VMH, ventromedial hypothalamus; i.c.v., intracerebroventricular.
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depot gets recombined during limb development. In contrast,
Prx1 does not trace the majority of brown adipocytes or any
visceral adipocytes (204). Thus, it is useful because of its
relative specificity, especially compared to adiponectin-cre, which
traces all adipocytes including marrow adipocytes (Figure 5A),
and a range of BMSC precursors (6). Another advantage to
this system are inducible Cres. As an example, Prx1-ER-cre,
where Cre expression is activated in Prx1 positive cells by
tamoxifen injection. These types of constructs allow for the
timed induction of the reporter. A caveat to be considered
when using tamoxifen and ER-inducible cre-drivers, however,
is that the dose of tamoxifen required to efficiently activate
Cre expression can be 100–1,000 times greater than required
to activate estrogen receptors. A single dose of tamoxifen is
reported to have irreversible effects on the uterus. Furthermore,
tamoxifen crosses the blood brain barrier to regulate energy
metabolism, is a potent immune modulator in mice, and can
induce bone marrow failure (205–207). Investigators who choose
to use tamoxifen in spite of its potent estrogen receptor-
mediated actions, should be advised to include a no treatment
control as well as a tamoxifen-treated/no Cre control. Equally
important is the nature of the reporter gene used. For example,
adipocytes possess little cytoplasm relative to other cell types,
therefore cytoplasmic reporters such as LacZ are not optimal for
tracing adipocytes. Instead, membrane-targeted reporters such as
mT/mG (membrane Tomato/membrane GFP) provide superior
results (208, 209). For extensive discussions on this topic see
Jeffery et al. (210) and Sanchez-Gurmaches et al. (211).
FIGURE 5 | Lineage tracing of bone marrow adipocytes and bone marrow stromal cells. (A) Adiponectin-cre:mT/mG mice received a single dose of x-irradiation
(1,000 rads) to induce bone marrow adipogenesis. Following irradiation, the mice were reconstituted by an intravenous. injection of 106 syngeneic bone marrow cells
to prevent radiation induced bone marrow damage. Bone marrow was collected from the femur as an intact plug, stained with LipidTox (fluorescent lipophilic dye), and
marrow adipocytes visualized by confocal microscopy. Greater than 95% of the cells were eGFP+ indicating they were traced by expression of Adiponectin. (B) The
femur from Twist-2-cre:mT/mG mice was isolated, the femoral head removed and the bone fixed in 4% paraformaldehyde overnight. The bones were then immersed
in 30% sucrose for 3–4 days, then placed in optimal cutting temperature compound, and frozen. Five to 10 µm thick-sections were imaged by confocal microscopy.
Columns of growth plate cartilage cells were eGFP+. In the bone marrow (outlined by arrows and appearing red), a small number of eGFP+ cells can be seen. In
addition, approximately 50% of osteocytes (*bone, appearing black) were also eGFP+. Cells that were eGFP+ were traced by the expression of Twist-2.
Frontiers in Endocrinology | www.frontiersin.org 23 February 2020 | Volume 11 | Article 65
Tratwal et al. BMAS Methodologies Working Group Report
Once the Cre-reporter has been selected, which will be
dictated by the demands of the experiment, either an ex-vivo or
in situ approach can be taken.
The ex-vivo approach involves dissecting out the femur,
cutting off the femoral head and removing the distal epiphysis
above the growth plate. A 20-gauge needle can then be inserted
down the medullary canal (from proximal to distal), and
punching out the needle through the distal growth plate. Because
the distal growth plate is intact this causes the bone marrow
to fill the needle. The needle is then attached to a syringe and
the marrow plug can then be deposited on a microscope slide
by depressing the barrel of the syringe. The adipocytes in the
marrow plug can then be prepared for imaging by confocal
microscopy. Femora are preferred for this technique because
they are fairly uniformly cylindrical along the length of the bone
making them amenable to boring.
Advantages: (1) This is a straight forward simple method
that requires no specialized equipment, with the exception of
the confocal microscope; (2) The method is rapid. It avoids
the requirement of decalcification or sectioning; (3) Using
mT/mG reporter mice, in addition to tracing mature marrow
adipocytes, will show whether marrow adipocyte precursors
(GFP+) expressed the gene of interest; (4) The marrow
adipocytes, in the marrow plug, can be stained with a fluorescent
lipophilic dye (i.e., LipidTOX) allowing for easy identification of
the mature adipocytes. This also allows for better determination
of cell counts and size. This approach can be combined
with immunofluorescence to co-stain for other cell markers
if desired.
Challenges: (1) Because adult mice (C57BL/6 background)
have few marrow adipocytes in the femur, induction of marrow
adipogenesis is recommended. However, the choice of which
induction protocol to be used (x-irradiation, high fat diet feeding,
feeding with a methionine restricted diet or a rosiglitazone
containing diet, see Tables 8, 9) will depend on the experimental
design; (2) The femoral medullary canal in adult mice is the
only site sufficiently large to collect a workable bone marrow
plug; (3) Because the cells are removed from the marrow their
anatomical location, especially as it relates to trabecular bone and
the endosteum is lost.
The second, in situ, approach maintains anatomical location
with respect to the growth plate and endosteum, but by
maintaining the calcified bone matrix, introduces its own
complications. Although the in situ approach involves collecting
fresh femurs, from that point, the method varies significantly
from investigator to investigator. The bones can be fixed
in paraformaldehyde overnight and then given a partial
decalcification in EDTA, sucrose incubation follows, and
then embedding in either a cryomedia or carboxymethyl
cellulose, followed by frozen sectioning (Figure 5B). Some
of the best images have been acquired using a tape-transfer
system and cutting 10–30µm sections (137, 199–201). Other
investigators have even used paraffin embedding instead of
frozen sections, although this necessitates the use of antibodies,
even in fluorescence reporter mice (5). After sectioning,
the tissue can then be stained with the desired antibody-
conjugate (direct i.e., GFP, or indirect using a secondary
fluorescent antibody or biotin-avidin conjugate), and imaged
by fluorescence or confocal microscopy. However, the fixation
and decalcification can vary greatly form investigator to
investigator, including some who use no fixation and rapid
freezing (200). In addition, to immunofluorescent staining,
transient fluorescent reporter mice (e.g., Zfp423-EGFP)
or Cre/Lox lineage tracing fluorescent reporter mice can
be used.
Advantages: (1) The major advantage to this method is that
it allows for direct visualization of the cells within intact bone.
Thus, the spatial relationship between marrow adipocytes, other
cells, and bone is maintained; (2) Using mT/mG reporter mice
can be a significant advantage; (3) Mature marrow adipocytes can
be imaged.
Challenges: (1) This method requires expertise and experience
in bone histology and specialized histologic equipment (e.g.,
tungsten-carbide knifes to section bone); (2) Sectioning small
bones (e.g., distal tibia and caudal vertebrae) can be difficult; (3)
Difficulties using the tape-transfer systems have been reported;
(4) The embedding techniques and section preparation often
exclude the combined use of lipid-tracing dyes.
It is clear that great progress in lineage tracing of marrow
adipocytes has been made during the last few years, due to
advances such as the Cre/Lox system. Our ability to delineate
cells in the bone marrow adipocyte lineage will only get better
with the advent of more specific Cre-drivers and more robust
reporters. Refinements in our ability to process bone to make
it more accessible to these methods will result in an even
better understanding of the lineage, how it relates to other
mesenchymal lineage cells, and the myriad of other cells in
bone marrow.
In vivo Modulation of BMA
BMAT is a complex and dynamic depot that is highly regulated
and can affect the function of other tissues/organs. Whether
presence of BMAT is necessary for normal physiological
responses is still controversial. While some studies have shown
that BMAT negatively influences bone mass, a study in BMAT-
deficient KitW/W−v (BMAT−) mice suggested that the absence of
BMAT did not have any relevant effect on ovariectomy-induced
bone loss (22). However, a recent study in BMAT− male mice
has shown that absence of BMAT exacerbated bone loss during
hindlimb unloading (212).
The expandability of BMAT is regulated by nutritional
and environmental factors, aging, endocrine signals, and
pharmacological agents. Here, we critically summarize
experimental models used to study in vivo regulation of
BMAT development and function.
Nutritional and Environmental Interventions
In C57BL/6J mice, a strain susceptible to obesity and diabetes,
HFD feeding induces also BMAT expansion (174, 175).
When diet-induced obesity (DIO) is reversed by switching to
normal chow diet (NCD) to mimic weight loss, the HFD-
induced BMAT recedes (175). Some of these alterations are
microbiota-dependent (195). The alterations induced by the
HFD on BMAT gene expression differ from that observed
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in peripheral adipose tissues. In contrast to visceral WAT,
pro-inflammatory gene expression was decreased while the
expression of genes of the insulin signaling pathway increased
in BMAT of HFD-fed mice, suggesting a differential metabolic
regulation of BMAT adipocytes (161). Walji et al. (213)
used microfibril-associated glycoprotein-1 (MAGP1) deficient
(Mfap2−/−) mice that develop adult-onset obesity that precedes
insulin resistance. In these mice, BMAT increased relative to WT
mice coincident with the development of insulin resistance, and
not with excess peripheral adiposity, hyperglycemia, change in
trabecular bone volume or hematopoiesis.
Exercise is a life-style intervention proposed to
prevent/counteract obesity-associated BMAT expansion
(Table 8). Voluntary wheel running in C57BL/6 fed NCD or
HFD demonstrated that exercise prevented the increase in BMAT
acquisition (176). Styner et al. (189) found that exercise (alone
or in combination with rosiglitazone) reduced BMAT volume
and upregulated UCP1 expression in whole tibia (Table 9).
Exercise can also reverse the increase of BMAT observed in
previously obese animals (HFD-fed for 3 months) by decreasing
both adipocyte number and size (63). Exercise was associated
with higher trabecular and cortical bone quantity in lean and
obese mice, but HFD itself did not influence bone quantity.
Importantly, a recent study, also provided evidence that physical
exercise modulates vertebral BMAT in humans (214).
The differential in vivo regulation of BMAT by nutritional
status also occurs in animal models of caloric restriction (CR).
In contrast to what is observed in visceral or subcutaneous WAT,
BMAT is preserved or even increased in states of CR [(35, 177,
178, 183); Tables 8, 9]. Indeed, CR (30%) in young growing
mice alters bone formation, but despite having a lower body
weight and body fat percentage, they exhibit a dramatic increase
in BMAT (35). In patients with anorexia nervosa, CR is also
associated with increased BMAT (215, 216). However, in New
Zealand rabbits moderate or extensive CR did not cause BMAT
expansion (177). It has been suggested that the increase in BMAT
is especially prominent when nutrient deprivation occurs during
periods of skeletal growth, such as childhood or adolescence
(178). This period of rapid skeletal growth may already be poised
for BMAT development as this is also a time of rapid baseline
BMAT accumulation (217).
The expansion of BMAT during CR has also been associated
with changes in several neuroendocrine factors that are
modulated in response to energy deprivation. The decrease
in leptin that occurs during CR-induced weight loss may
account for the increased BMAT. Indeed, BMAT is increased
in leptin-deficient ob/ob mice (218), and subcutaneous leptin
treatment induces loss of BMAT adipocytes and increases
bone formation in these mice (181). Moreover, peripheral
leptin therapy is effective in reversing the increased BMAT
observed in type 1 diabetic mice and CR models, but does
not stop the bone loss that occurs concomitantly [(182, 183);
Table 9]. Furthermore, central injections of leptin into the
ventromedial hypothalamus (VMH) of Sprague-Dawley rats,
as well as leptin gene therapy (intraventricular administration
of recombinant adeno-associated virus (rAAV)-leptin gene) to
ob/ob mice also reduced BMAT (184, 185). Interestingly, mice
with selective deletion of the leptin receptor (Lepr) in limb bone
marrow stromal cells (Prx1-Cre;Leprfl/fl mice) exhibited normal
body mass and hematopoiesis, but have decreased BMAT, and
increased osteogenesis (219). Moreover, Prx1-Cre;Leprfl/fl mice
were protected from the HFD-increases in BMAT and reductions
in osteogenesis. It therefore appears that hypothalamic and
peripheral leptin signaling may have different or multiple effects
on adipogenesis within bone marrow.
Aging
Increased BMAT is also observed during aging, and has
been negatively correlated with bone health, and sometimes
precipitates impaired hematopoiesis in animals (5, 220) and
humans (221–223). Dietary strategies have also been proposed
to counteract the increased BMAT associated with aging, and
combination of conjugated linoleic acid with fish oil can
decrease age-associated BMAT in C57BL/6J mice (179). Dietary
methionine restriction (MR) increases longevity in rodent
models, however MR promotes BMAT accumulation in contrast
to WAT reduction (180).
Endocrine Regulation
From an endocrine perspective, bone and BMAT metabolism
are tightly linked and therefore BMAT is under extensive
hormonal regulation. First of all, already a long time ago
it has been observed that ovariectomy increases BMAT in
animals (224) and ovariectomy is now commonly used to
induce BMAT in animal models. These observations have
been extended to humans, as BMAT increases during aging
and this increase is accelerated in women around the time
of menopause (225). Post-menopausal hormonal replacement
therapy with estradiol, both long term (1 year) and short
term (2 weeks) decreases BMAT in women (33, 226), showing
that indeed estradiol is an important regulator of BMAT. At
the same time that estradiol secretion by the ovaries ceases,
compensatory follicle stimulating hormone (FSH) secretion
by the pituitary gland increases. In addition to the effect of
hormonal replacement therapy, also FSH blocking therapy has
been shown to decrease BMA inmice (83). In addition to gonadal
hormones, glucocorticoids have a profound effect on adipose
metabolism and this also holds true for bone marrow adiposity.
Cushing’s disease, defined by increased adrenocorticotropic
hormone (ACTH) production by a pituitary adenoma and
therefore hypercortisolemia, increases BMAT and this reverses
again following surgical cure by removal of the pituitary
adenoma (227). Also, long-term glucocorticoid treatment leads
to increased BMAT (228) and can be used to induce BMAT
in animal models. Finally, parathyroid hormone, an important
regulator of bone metabolism and potent osteoanabolic drug,
also has an effect on BMA. Teriparatide treatment in osteopenic
women reduces BMAT (229) and animal studies showed that
this effect can be recapitulated by genetic deletion of the
parathyroid hormone receptor in skeletal stromal cells (56).
Interestingly, additional studies from the Rosen lab showed that
the effect of PTH is not only on the differentiation of the
SSC into the adipocytic lineage, but that Parathyroid Hormone
(PTH) can also induce lipolysis in BM adipocytes (230). In
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addition, growth hormone (GH) is an important regulator of
skeletal growth and growth hormone deficiency or resistance
has been associated with changes in BMAT. In growing rats,
hypophysectomy dramatically increases BMAT and this could
not be reversed by treatment with either estradiol, thyroid
hormone, cortisol or Insulin Growth Factor-1 (IGF-1), but was
completely reversed by treatment with GH (231). In healthy,
premenopausal women, vertebral BMAT measured with 1H-
MRS was inversely associated with IGF-1 concentrations, but not
stimulated GH concentrations (232). However, treatment with
recombinant GH for 6 months in premenopausal obese women,
did not change BMAT, although there was a significant difference
between the GH treated and placebo treated groups due to
the decrease in BMAT in the placebo group (233). Therefore,
the role of GH in the regulation of BMAT in adult humans
remains uncertain and studies in children during growth have not
been performed.
BMAT is not only regulated by hormones, but also acts as an
important endocrine organ itself. Cawthorn et al. (234) found
that increased BMAT significantly contributes to the higher
circulating adiponectin levels during CR. Moreover, studies in
Ocn-Wnt10b mice, which resist BMAT expansion during CR,
demonstrated that increased BMAT is required for the elevated
circulating adiponectin in this condition. Furthermore, BMAT
and adiponectin levels increase in patients undergoing therapy
for ovarian or endometrial cancer, despite no change in total
fat mass (234). Increased adiponectin levels and BMAT volume
were also observed in DIO WT (C57BL/6J) mice treated with
Rosiglitazone. However, female Ocn-Wnt10b mice treated with
Rosiglitazone had mildly blunted hyperadiponectinemia (191)
while males did not, suggesting a sex-specific response.
Pharmacological Modulation
Several drugs also regulate BMAT. PPARγ is a master
transcription factor for adipocyte differentiation, and treatment
with the insulin-sensitizing drugs thiazolidinediones (TZDs),
which are PPARγ agonists, affects marrow adiposity. As shown
in Table 9, treatment with several PPARγ agonists such as
Rosiglitazone and Troglitazone enhanced BMAT in different
animalmodels (187, 188). However, the effects of TZDs on BMAT
seem to be strain-specific (190) and age-dependent, favoring
BMAT accumulation in older mice rather than in young-growing
animals (188). In ovariectomized (OVX) rats, treatment with
rosiglitazone (BRL49653) exacerbated bone loss and increased
BMAT (186). On the other hand, several studies have shown
that treatment with PPARγ agonists increased BMAT without
affecting trabecular bone volume, suggesting that adipogenesis
and osteogenesis can be regulated independently in vivo (187).
Similarly, netoglitazone administered to 6-month-old C57BL/6
mice had a strong adipogenic induction with no change in the
trabecular architecture and modest decreases in cortical bone
mineralization (235). In contrast, a reduction in BMAT has
been observed in all studies administering PPARγ antagonists
after chemo/radiotherapy, which are potent inductors of BMAT
[(37, 192–194, 196, 236); Table 8]. Moreover, genetic models
of PPARγ loss show a pronounced increase in bone mass with
extramedullary hematopoiesis (237, 238). The effects of BMAT in
the recovering of hematopoietic compartment seem apparently
contradictory, possibly due to the differential effects of distinct
BMAd subtypes and differentiation stages in hematopoietic
progenitor support [reviewed in (239, 240)]. Methodologically, it
is to be noted that although effective in reducing BMAT, the most
commonly used PPARγ “antagonist” for in vivo experimentation,
Bisphenol A Diglycidyl Ether (BADGE), has partial PPARγ
agonist effects and is a potential endocrine disruptor receptor
anti-androgenic and pro-estrogenic properties (241–243). It is
therefore recommended that future in vivo studies use a more
specific PPARγ antagonist such as GW9662 (196).
BMAT thus accumulates following hematopoietic marrow
ablation. A wave of BMAT precedes hematopoietic repopulation
and peaks from 2 to 3 weeks after whole-body radiation
depending on dose and recipient characteristics (700–1,000Gy)
(193, 202). BMAT is then lost and the timing of recovery depends
on the radiation dose and on the number of hematopoietic
cells used for the rescue. Sublethal models which do not
require hematopoietic rescue have also been developed with 5-
fluorouracil or cytarabine treatments (194, 236). Both radiation
and chemotherapeutic treatments induce dramatic increases in
BMAT also in patients (234, 244), whereas certain disorders
of inefficient hematopoiesis (e.g., W/Wv mice) are associated
with greatly reduced BMAT and a modified lipid composition
of the stroma (245, 246). The biological implications of BMAT
in neoplastic progression within the BM microenvironment are
only beginning to unravel (247–251).
Sympathetic Regulation
A very important issue when studying the in vivo modulation
of BMAT is to consider the region-specific variation in the
properties of the skeletal adipocytes, as already discussed in the
BMAT isolation section. The studies of Scheller et al. (12) in
mice strongly support the existence of a constitutive (cBMAT)
and a regulated (rBMAT) depot. cBMAT is in the distal long
bones fills the medullary canal from the tibia-fibular junction
into the malleolus and caudal vertebrae, histologically resembles
WAT, appears rapidly in the early postnatal period, does not
usually respond to stimuli or pathophysiological changes (202),
though it can reduced over several months with thermoneutrality
(252). In contrast, rBMAT is situated in the proximal regions
of long bones and in spinal vertebrae, develops after cBMAT,
and is interspersed with hematopoietic cells. rBMAT increases or
decreases in various conditions (DIO, aging, CR, etc.) (253).
The study of Scheller et al. (12) also revealed that knockout
of PTRF (Ptrf−/− mice, a model of congenital generalized
lipodystrophy 4) selectively inhibits formation of rBMAT
adipocytes without affecting cBMAT, which could be one step
toward generation of a genetic model of rBMAT ablation (12).
The lack of response of BMAT adipocytes to lipolysis during
energy deprivation has been attributed to resistance to β-
adrenergic stimulation, but this effect also shows region-specific
differences. Acute fasting (48 h) decreases cell size of BMAT
adipocytes within the proximal tibia but not within the tail
vertebrae in Sprague-Dawley rats (178). Moreover, BMAT from
distal tibia and tail vertebrae of these rats resists β-adrenergic-
induced phosphorylation of Hormone-Sensitive Lipase (HSL)
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and/or perilipin, which are required for stimulation of lipolysis.
Furthermore, treatment of C3H/HeJ mice with CL316,243, a
β3-AR agonist, caused remodeling/beigeing of WAT, but only
moderate remodeling of lipid droplets in BMAT of proximal
tibia without affecting mid or distal tibia (Table 9). Furthermore,
β-adrenergic stimulation through cold exposure shows lipolytic
response by rBMAT (decreased rBMAT in the tibial epiphysis
and in the proximal tibia) while cBMAT remained unchanged
(12). Therefore, these data suggest that the lipolytic response to
β-adrenergic stimulation is more pronounced in rBMAT than in
cBMAT (178).
Another important factor to take into account when designing
and interpreting studies about in vivo BMAT regulation is
the effect of housing temperature. Most of the studies in
mouse models are performed at room temperature (RT, around
22◦C), which is below the thermoneutral temperature for
mice (around 32◦C). Therefore, RT housing can increase non-
shivering thermogenesis by the sympathetic outflow and the
activation of UCP1 in BAT (254, 255) showed that thermoneutral
housing not only reduces UCP1 expression in BAT, but also
increase BMAT and the percentage of body fat as compared
with RT-housed mice. Therefore, the mild cold stress induced
by RT-housing could be a non-considered confounding factor in
mice studies.
In vivo Modulation Challenges
All these studies have demonstrated that BMAT expansion
accompanies metabolic dysfunction. However, many
physiopathological changes take place in these processes,
and dissecting the role of BMAT expansion from the role of
peripheral adipocytes and other metabolic perturbations make
mechanistic studies a challenge. Furthermore, the divergent
BMAT responses to different strains/species suggest the
existence of a strong genetic background effect, which should
be considered when designing studies, highlighting once more
the importance of adhering to the BMAS minimal reporting
guidelines when communicating results (see Table 1). Possibly,
standard in vivo experimental conditions need to be defined
for inter-laboratory comparisons. As we continue to identify
the physiological processes that underlie the formation of
BMAT and the environmental and genetic cues that control its
accumulation, it is becoming increasingly evident that BMAT
may be heterogenous.
Finally, in spite of their limitations, wider use of available
genetic models of non-selective BMAT depletion (e.g., Ptrf−/−,
W/Wv), which have lesser metabolic phenotypes than severely
lipodystrophicmice (e.g., A-ZIP/F), should advance the field until
models of highly-specific BMAT depletion can be developed.
Furthermore, it is paramount to consider that the BMA,
bone, vascular and hematopoietic compartments are tightly
interlinked within the BM, such that in vivo analysis requires
functional measurements of all four compartments to reach
mechanistic conclusions.
BIOBANKING
The BMAS Working Group on Biobanking has the ambition
to generate standardized approaches toward isolation,
characterization and long-term storage of tissues/cells related
to BMA and their associated data and annotations. Although
difficult to achieve due to several challenges (see below), creating
minimal standards to isolate and characterize BMAds as well
as freezing protocols for long-term storage should significantly
reduce variability in outcomes between studies and laboratories.
This is especially important to ensure viability and conservation
of heterogeneity in cell-based assays, and to ensure sample
stability for chemical analysis including mass spectrometry.
Most importantly, unified biobanking standards along with the
protection of associated data will enable responsible use and
exchange of samples for comparative and larger-scale studies.
Ultimately, the field will benefit from improved applicability
of animal and human BMA-related samples, which may better
facilitate the discovery of novel therapeutics to target BMA.
In a complementary fashion to the BMAS Working Group in
Methodologies, one of the foci of the BMAS BiobankingWorking
Group will be to congregate methodologies related to the
collection, freezing/thawing and long-term storage of BMAds.
Additional aspects of biobanking that the working group will
scrutinize are privacy regulations regarding participants/patients,
data protection and ethical guidelines to facilitate collaborative
efforts. Main challenges toward this objective are briefly
introduced below.
Isolation of BMAds
Different types of materials have been and will be employed
to study BMA, including BM aspirates, biopsies, specific cell
types, BM plasma fraction, etc. After having defined these,
recommended standard procedures are required regarding BMA
isolation, processing and characterization. For example, isolation
protocols vary substantially between laboratories (digestion with
collagenase or other enzymes, incubation times, etc.). In addition,
it is important to distinguish protocols for animal studies vs.
human materials as BMA is different in composition, location,
metabolism and regulation. For human bone marrow–related
samples, recommended patient screening should be additionally
established (HIV, Hepatitis B and C virus). Finally, minimal
standards should also be established for sample annotation,
which should include description of the site of collection, method
of collection and isolation, including time and type of digestion,
time from collection to freezing, etc.
Characterization of BMAds
One of the biggest challenges is to define a healthy control set,
especially for human samples (see Table 1). What is regarded as
normal population and a standard site of collection and how do
we define this? What is the minimal set of parameters required
to define such a set? One solution is to propose a minimal set
of specific surface molecules, gene expression markers and/or
other biomarkers (e.g., lipid profiles) to facilitate comparisons
and thus also multicenter studies. Some specific markers have
been proposed (adipokine markers, absence of hematopoietic,
endothelial, and hematopoietic markers) but additional species-
specific markers are needed to be able to characterize BMAds in
a uniform and reliable fashion.
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Long-Term Storage of BMA-Related
Samples
To date it has proven impossible to freeze BMAds, and the only
access point to retrospective samples relies on the identification
of adipocyte ghosts in paraffin blocks. Tissue samples containing
adipocytes are being collected but these require purification
and/or digestion steps before freezing. On the other hand,
storage of precursor cells (SSCs) may poorly reflect the BMA
situation at the time of isolation, most often due to cellular
expansion (and deviation) in vitro before or after freezing.
In order to create as much homogeneity as possibly, it is
vital to define freezing and thawing procedures employed with
a minimum of interfering steps as well as viability and cell
growth/differentiation characteristics of previously stored BMA
samples. Non-frozen samples, including paraffin blocks, may
pose less issues, but still homogeneity in tissue processing and
database management are required to optimize storage and
exchange of samples.
Ethical Issues and Data Protection
With the installment of the General Data Protection Regulation
(GDPR) in 2018 (EU GDPR Portal (website), accessed August
27, 2019, http://eugdpr.org) the protection of people and
data has become more stringent. Trying to come up with a
standardized procedure toward biobanking will face challenges,
including different national regulations, institutionalized
rules, etc. Ethical guidelines varying between countries should
be dealt with to assess the possibility to generalize ethical
topics into one document for samples to be collected in
the future. Related to this, a general template for informed
consent and awareness of mutual use of obtained samples
by all involved may improve standardization and the
possibility to share samples, which is especially relevant
in the context of rare diseases. A BMAS consortium-
wide material transfer agreement may be instrumental
for this.
Issues related to data protection include the assurance
that participant/patient data remains anonymous at all costs.
Although the consciousness around this subject is increasing,
the working group will assess these issues in detail and will
aim to propose a comprehensive recommended protocol to
safeguard anonymity and data protection that originates from
any of the laboratories. Data obtained in the European union
(EU) often cannot be stored on servers outside the EU and
similar regulations may apply to different continents as well.
Therefore, a robust data management plan needs to be installed
that can explore and potentially overcome challenges such as
decentralized storage of samples and associated files.
In conclusion, biobanking, and methodological challenges are
tightly linked. Minimal standards and international overarching
ethical guidelines for BMA sample collection and data protection
will be critical to increase the quality of fundamental and
multicenter clinical studies, and interpret with greater confidence
the outcome and impact of BMA research within the next
few years.
CONCLUDING REMARKS
Specific methodologies for the study of BMA have been
developed in the last decade, paralleling the increasing interest
in the field. Gold standard methodologies currently exist for
the assessment of BMA ex vivo, in vivo and in vitro (e.g.,
histomorphometry and OsO4− 3D contrast-enhanced µCT for
ex vivo, WFI and 1H-MRS MRI sequences for in vivo studies,
lipid-dye-based and RT-qPCR-based assessment for assessment
of in vitro BM adipogenesis) and emerging techniques may
soon come to complement or substitute these gold standards
(i.e., digital pathology algorithms for histomorphometry, POM-
based contrast-enhanced CT for ex vivo imaging, dual energy
CT for in vivo imaging as well as more reproducible parameters
for in vivo MRI spectroscopy, label-free or 3D microscopy and
microspectroscopy for in vitro imaging, or 3D adipose organoids
for in vitro cultures).
However, great challenges still remain. First, given the
inherent fragility of BMAds and their difficult access within
the bone, protocols for extraction, ex vivo handling, and in
vitro culture/differentiation of BMAds or BMSC progenitors
vary greatly. Thus, recommended standardized protocols for
in vivo modulation and extraction, minimal standards for
BMAd purity assessment, and standardization ofmethod-specific
thresholds for BMA detection would greatly increase inter-study
comparison and multi-site collaborations. Second, given the
number of factors that affect BMA mass, and possibly type (e.g.,
skeletal location, gender, age, strain, nutritional status, metabolic
state, exercise, ambient temperature, isolation technique), great
attention needs to be paid in careful annotation and reporting of
these confounding factors for all BMA scientific output. Third,
in order to move forward the functional understanding of BMA,
tools for the specific ablation of BMAds are urgently needed to
uncouple the local BMA-effects from the metabolic effects of
systemic lipodystrophy.
The BMAS Working Group in Methodologies and the
collaborative BMAS community at large present the opportunity
to reach methodological consensus guidelines and propose
minimal standards that would strengthen the quality of
our scientific output, increase comparability and prepare the
field for multi-site preclinical and clinical studies which can
pave the way to sound clinical translation. As a first step,
incorporation of the BMAS nomenclature guidelines presented
in the accompanying piece of this issue (31) and adherence to
the methodology reporting guidelines presented here (Table 1)
will ensure a common language for our community. In addition,
we would like to invite readers to contribute by commenting
on this review in the comments section of the “Frontiers in
Endocrinology” website.
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